Alogliptin vs Linagliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Alogliptin · Nesina

Marketed by Takeda Pharmaceutical Company and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00286429 · Phase 3 · completed

The 390-participant trial was randomized, quadruple-blind, and placebo-controlled, with 130, 131, and 129 participants assigned to placebo, alogliptin 12.5 mg, and alogliptin 25 mg, respectively. Both primary HbA1c comparisons were statistically significant in favor of alogliptin, but HbA1c is a surrogate measure, so the evidence does not establish a strong clinical-outcome grade.

Next expected readout: December 2026 · NCT07093476 (registry estimate)

Reported efficacy

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26 (Baseline and Week 26): Alogliptin 25 mg 0.091 percentage of HbA1c (Standard Deviation 0.2879) vs Placebo -0.011 percentage of HbA1c (Standard Deviation 0.2809) (missed)

Result source: NCT02856113

Linagliptin · Tradjenta

Marketed by Boehringer Ingelheim and partners

Approved in Type 2 Diabetessmall molecule
Partial signal

NCT00602472 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 1,058 participants, and its primary endpoint was met: adjusted HbA1c change was −0.72% with linagliptin versus −0.10% with placebo (p<0.0001). The evidence is considered moderate because HbA1c is a surrogate measure rather than a hard clinical endpoint.

Reported efficacy

The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): The First 3-point Major Adverse Cardiovascular Events (3P-MACE) (From randomization until individual day of trial completion, up to 432 weeks): Linagliptin 20.7 Events/ 1000 patients-years vs Glimepiride 21.2 Events/ 1000 patients-years (met)

Result source: NCT01243424

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAlogliptinLinagliptin
HbA1c, change-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366
Body weight, change (kg)0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814
HbA1c below 7%63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037
Fasting plasma glucose, change-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814
3-point MACE (% with event)11.3% vs 11.8%−0.5 vs placebon 2701NCT0096870820.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532

HbA1c, change

Alogliptin
-0.7% vs -0.1%−0.6 vs placebo25 mg QD · wk 26 · n 126NCT00286429
285 other results
  • -0.6% vs -0.0% 25 mg QD · wk 26 · n 128 · Phase 3 · primary NCT00286455
  • 0.1% vs -0.0% 25 mg · wk 26 · n 54 · Phase 3 · primary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.9% vs -0.1% 25 mg · wk 26 · n 123 · Phase 3 · primary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 26 · n 195 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 26 · n 203 · Phase 3 · primary NCT00286442
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 130 · Phase 3 · primary NCT00286429
  • -0.6% vs -0.0% 12.5 mg QD · wk 26 · n 131 · Phase 3 · primary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 26 · n 104 · Phase 3 · primary NCT01023581
  • -0.6% vs -0.1% 12.5 mg · wk 26 · n 122 · Phase 3 · primary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 26 · n 196 · Phase 3 · primary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 26 · n 210 · Phase 3 · primary NCT00286442
  • -1.3% vs -0.1% 25 mg + 15 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 25 mg + 30 mg · wk 26 · n 124 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · primary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 102 · Phase 3 · primary NCT01023581
  • -1.6% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 111 · Phase 3 · primary NCT01023581
  • -1.3% vs -0.1% 12.5 mg + 15 mg · wk 26 · n 130 · Phase 3 · primary NCT00328627
  • -1.4% vs -0.1% 12.5 mg + 30 mg · wk 26 · n 128 · Phase 3 · primary NCT00328627
  • -1.6% vs -0.1% 12.5 mg + 45 mg · wk 26 · n 127 · Phase 3 · primary NCT00328627
  • -1.0% vs -0.4% wk 16 · n 90 · Phase 3 · primary NCT01289119
  • -0.9% vs -0.4% wk 16 · n 98 · Phase 3 · primary NCT01289119
  • -0.8% vs -0.4% wk 16 · n 60 · Phase 3 · primary NCT01289119
  • -1.0% vs -1.1% 25 mg · wk 26 · n 160 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 52 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 25 mg · wk 104 · n 382 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 303 · Phase 3 · primary NCT00432276
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 303 · Phase 3 · primary NCT00432276
  • -1.0% vs 0.0% 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · primary NCT01263483
  • -1.7% vs -1.1% 25 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 52 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs -0.6% 12.5 mg · wk 104 · n 371 · Phase 3 · primary NCT00856284
  • -0.7% vs 0.3% 25 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -1.0% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · primary NCT01318070
  • -0.9% vs 0.0% 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · primary NCT01263483
  • -1.6% vs -1.1% 12.5 mg + 30 mg · wk 26 · n 158 · Phase 3 · primary NCT00395512
  • -0.6% vs 0.3% 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · primary NCT01318083
  • -0.9% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · primary NCT01318070
  • 0.3% vs 0.8% 25 mg · wk 52 · n 62 · Phase 3 · secondary NCT02856113
  • 0.1% vs 0.5% 25 mg · wk 39 · n 62 · Phase 3 · secondary NCT02856113
  • -0.7% vs -0.2% 25 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.2% 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 20 · n 203 · Phase 3 · secondary NCT00286442
  • -0.2% vs -0.2% 25 mg · wk 18 · n 62 · Phase 3 · secondary NCT02856113
  • -0.8% vs -0.2% 25 mg QD · wk 16 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 25 mg · wk 16 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 25 mg QD · wk 16 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286429
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286455
  • -0.4% vs -0.3% 25 mg · wk 12 · n 62 · Phase 3 · secondary NCT02856113
  • -0.5% vs 0.1% 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -0.9% vs -0.3% 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • -0.8% vs -0.2% 25 mg QD · wk 12 · n 195 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 25 mg QD · wk 12 · n 203 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 25 mg QD · wk 8 · n 128 · Phase 3 · secondary NCT00286455
  • -0.5% vs 0.1% 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 25 mg · wk 8 · n 123 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 25 mg QD · wk 8 · n 195 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 25 mg QD · wk 8 · n 201 · Phase 3 · secondary NCT00286442
  • -0.6% vs -0.3% 25 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286455
  • -0.3% vs 0.1% 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 25 mg · wk 4 · n 110 · Phase 3 · secondary NCT00328627
  • -0.5% vs -0.1% 25 mg QD · wk 4 · n 176 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 25 mg QD · wk 4 · n 187 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 20 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.2% 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.1% 12.5 mg QD · wk 20 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.2% 12.5 mg QD · wk 16 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.3% 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.1% 12.5 mg QD · wk 16 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 12 · n 130 · Phase 3 · secondary NCT00286429
  • -0.6% vs -0.1% 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.7% vs -0.2% 12.5 mg QD · wk 12 · n 210 · Phase 3 · secondary NCT00286442
  • -0.8% vs -0.3% 12.5 mg QD · wk 8 · n 130 · Phase 3 · secondary NCT00286429
  • -0.5% vs -0.1% 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.6% vs 0.1% 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8% vs -0.3% 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -0.6% vs -0.2% 12.5 mg QD · wk 8 · n 210 · Phase 3 · secondary NCT00286442
  • -0.5% vs -0.3% 12.5 mg QD · wk 4 · n 116 · Phase 3 · secondary NCT00286429
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 123 · Phase 3 · secondary NCT00286455
  • -0.4% vs 0.1% 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg · wk 4 · n 114 · Phase 3 · secondary NCT00328627
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 182 · Phase 3 · secondary NCT00286494
  • -0.4% vs -0.1% 12.5 mg QD · wk 4 · n 188 · Phase 3 · secondary NCT00286442
  • -1.4% vs -0.2% 25 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.2% 25 mg + 30 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.2% 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 15 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 25 mg + 30 mg · wk 16 · n 124 · Phase 3 · secondary NCT00328627
  • -1.7% vs -0.3% 25 mg + 45 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 25 mg + 30 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 15 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.3% 25 mg + 30 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • -1.2% vs -0.3% 25 mg + 45 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 15 mg · wk 4 · n 116 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 30 mg · wk 4 · n 118 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 25 mg + 45 mg · wk 4 · n 112 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.2% 12.5 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.2% 12.5 mg + 30 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -1.6% vs -0.2% 12.5 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -1.3% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -1.5% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -1.4% vs -0.3% 12.5 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -1.4% vs -0.3% 12.5 mg + 30 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.5% vs -0.3% 12.5 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -1.4% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2% vs -0.3% 12.5 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 30 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.3% vs -0.3% 12.5 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -1.1% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -1.2% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -1.0% vs -0.3% 12.5 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 30 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -1.1% vs -0.3% 12.5 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -0.7% vs 0.1% alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -0.8% vs 0.1% alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -0.5% vs -0.2% 12.5 mg + 15 mg · wk 4 · n 120 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 30 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -0.6% vs -0.2% 12.5 mg + 45 mg · wk 4 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0% vs -0.4% wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -0.8% vs -0.4% wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -0.9% vs -0.4% wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.7% vs -0.4% wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.6% vs -0.2% wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -0.4% vs -0.2% wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -1% vs -1.2% 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.2% 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0% vs -1.0% 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.3% 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 25 mg · wk 78 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 65 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 25 mg · wk 91 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.7% 25 mg · wk 39 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.8% 25 mg · wk 26 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 25 mg · wk 20 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.5% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 303 · Phase 3 · secondary NCT00432276
  • -0.7% vs -0.0% 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.2% vs -0.0% 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.8% 25 mg · wk 16 · n 382 · Phase 3 · secondary NCT00856284
  • -0.9% vs -0.4% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 303 · Phase 3 · secondary NCT00432276
  • -1.7% vs -1.2% 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -0.7% vs -0.8% 25 mg · wk 12 · n 382 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 303 · Phase 3 · secondary NCT00432276
  • -1.6% vs -1.0% 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.6% vs -0.7% 25 mg · wk 8 · n 382 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.3% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 303 · Phase 3 · secondary NCT00432276
  • -1.2% vs -0.7% 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -0.4% vs -0.4% 25 mg · wk 4 · n 382 · Phase 3 · secondary NCT00856284
  • -0.6% vs 0.2% 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.1% Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 303 · Phase 3 · secondary NCT00432276
  • -0.8% vs -0.0% 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.6% vs -0.3% 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8% vs -0.7% 12.5 mg · wk 78 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 65 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 91 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.7% 12.5 mg · wk 39 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 26 · n 371 · Phase 3 · secondary NCT00856284
  • -0.8% vs -0.8% 12.5 mg · wk 20 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 16 · n 371 · Phase 3 · secondary NCT00856284
  • -0.7% vs -0.8% 12.5 mg · wk 12 · n 371 · Phase 3 · secondary NCT00856284
  • -0.6% vs -0.7% 12.5 mg · wk 8 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs -0.4% 12.5 mg · wk 4 · n 371 · Phase 3 · secondary NCT00856284
  • -0.4% vs 0.1% 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -0.4% vs -0.0% 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -0.1% vs 0.1% 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.2% vs -0.0% 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5% vs -1.2% 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -1.4% vs -1.2% 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -1.3% vs -1.0% 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0% vs -0.7% 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -0.5% vs 0.2% 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8% vs -0.2% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.5% vs -0.3% 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -0.3% vs 0.1% 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.5% vs -0.1% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -0.1% vs 0.1% 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.2% vs -0.0% alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -0.6% vs -0.0% 25 mg QD · wk 12.14 · n 45 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.7% vs 0.1% 12.5 mg QD · wk 12 · n 84 · Phase 2 · primary NCT01263470
  • -0.5% vs -0.0% 100 mg QD · wk 12.14 · n 44 · Phase 2 · primary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 12.14 · n 43 · Phase 2 · primary NCT00755846
  • -0.8% vs 0.1% 50 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.2% vs -0.0% 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · primary NCT00755846
  • -0.5% vs 0.1% 6.25 mg QD · wk 12 · n 79 · Phase 2 · primary NCT01263470
  • -0.7% vs 0% 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4% vs 0.0% 25 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.6% vs 0% 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.7% vs 0% 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3% vs 0.0% 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -0.4% vs -0.0% 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0% 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.5% vs 0% 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.1% vs 0.0% 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.3% vs -0.0% 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.2% vs 0% 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7% vs -0.4% 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.2% 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.4% 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 12.5 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.3% 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.7% vs -0.1% 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.2% 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.4% 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -0.8% vs -0.3% 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.3% 50 mg QD · wk 16 · n 91 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.1% 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9% vs -0.2% 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.4% 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.4% 6.25 mg QD · wk 48 · n 63 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.3% vs -0.3% 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.3% 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.5% vs -0.3% 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.3% 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.6% vs -0.1% 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.4% vs -0.2% 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Linagliptin
-0.6% vs 0.1%−0.6 vs placebo5 mg · wk 24 · n 618NCT00954447
129 other results
  • -0.7% vs -0.1% wk 24 · n 778 · Phase 3 · primary NCT00602472
  • -0.5% vs 0.1% wk 24 · n 513 · Phase 3 · primary NCT00601250
  • -0.6% vs -0.0% 5 mg · wk 24 · n 161 · Phase 3 · primary NCT01792518
  • -0.7% vs -0.2% 5 mg · wk 24 · n 196 · Phase 3 · primary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 24 · n 203 · Phase 3 · primary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 24 · n 179 · Phase 3 · primary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 24 · n 93 · Phase 3 · primary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 24 · n 160 · Phase 3 · primary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · primary NCT01087502
  • -1.1% vs -0.6% wk 24 · n 252 · Phase 3 · primary NCT00641043
  • -0.4% vs 0.3% wk 24 · n 333 · Phase 3 · primary NCT00621140
  • -0.9% vs -0.3% 25 mg + 5 mg · wk 24 · n 111 · Phase 3 · primary NCT02489968
  • -0.6% vs 0.1% 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · primary NCT01734785
  • -0.9% vs -0.3% 10 mg + 5 mg · wk 24 · n 103 · Phase 3 · primary NCT02489968
  • -0.7% vs 0.1% 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · primary NCT01734785
  • -0.6% vs -0.2% wk 24 · n 100 · Phase 3 · primary NCT02897349
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · primary NCT01183013
  • 0.3% vs -0.2% 5 mg · wk 26 · n 52 · Phase 3 · primary NCT03429543
  • -1.3% vs -1.6% 5 mg QD · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -1.3% vs -1.7% 5 mg QD · wk 24 · n 125 · Phase 3 · primary NCT01708902
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · primary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · primary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · primary NCT01183013
  • -2.1% vs -1.6% 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · primary NCT01708902
  • -2.3% vs -1.6% 2.5 mg / 1000 mg BID · wk 24 · n 141 · Phase 3 · primary NCT01708902
  • -2.2% vs -1.7% 2.5 mg / 500 mg BID · wk 24 · n 135 · Phase 3 · primary NCT01708902
  • -2.4% vs -1.7% 2.5 mg / 1000 mg BID · wk 24 · n 128 · Phase 3 · primary NCT01708902
  • -0.5% vs 0.1% 5 mg · wk 52 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0.1% 5 mg · wk 40 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 32 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 18 · n 618 · Phase 3 · secondary NCT00954447
  • -0.6% vs 0.0% 5 mg · wk 12 · n 618 · Phase 3 · secondary NCT00954447
  • -0.5% vs 0% 5 mg · wk 6 · n 618 · Phase 3 · secondary NCT00954447
  • -0.8% vs -0.1% wk 18 · n 778 · Phase 3 · secondary NCT00602472
  • -0.7% vs -0.2% 5 mg · wk 24 · n 168 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.2% 5 mg once daily · wk 24 · n 182 · Phase 3 · secondary NCT01215097
  • -0.7% vs -0.2% 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6% vs -0.1% 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.9% vs -0.4% 5 mg tablet · wk 18 · n 179 · Phase 3 · secondary NCT00996658
  • -0.8% vs -0.3% 5 mg · wk 18 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs 0.0% 5 mg · wk 18 · n 160 · Phase 3 · secondary NCT01084005
  • -0.6% vs -0.1% 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7% vs -0.1% 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.8% vs -0.3% 5 mg tablet · wk 12 · n 179 · Phase 3 · secondary NCT00996658
  • -0.7% vs -0.2% 5 mg · wk 12 · n 93 · Phase 3 · secondary NCT01194830
  • -0.6% vs -0.0% 5 mg · wk 12 · n 160 · Phase 3 · secondary NCT01084005
  • -0.5% vs -0.1% 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.5% vs -0.0% 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.6% vs -0.2% 5 mg tablet · wk 6 · n 179 · Phase 3 · secondary NCT00996658
  • -0.5% vs 0.1% wk 18 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.1% 5 mg · wk 6 · n 160 · Phase 3 · secondary NCT01084005
  • -1.1% vs -0.6% wk 18 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 18 · n 333 · Phase 3 · secondary NCT00621140
  • -0.8% vs -0.1% wk 12 · n 778 · Phase 3 · secondary NCT00602472
  • -0.5% vs 0.1% wk 12 · n 513 · Phase 3 · secondary NCT00601250
  • -0.8% vs -0.3% wk 12 · n 252 · Phase 3 · secondary NCT00641043
  • -0.5% vs 0.2% wk 12 · n 333 · Phase 3 · secondary NCT00621140
  • -0.7% vs -0.2% wk 6 · n 778 · Phase 3 · secondary NCT00602472
  • -0.4% vs 0.1% wk 6 · n 513 · Phase 3 · secondary NCT00601250
  • -0.4% vs -0.0% wk 6 · n 252 · Phase 3 · secondary NCT00641043
  • -0.4% vs 0.1% wk 6 · n 333 · Phase 3 · secondary NCT00621140
  • -0.6% vs -0.2% 5 mg · wk 6 · n 93 · Phase 3 · secondary NCT01194830
  • -0.5% vs 0.1% 5 mg · wk 26 · n 5 · Phase 3 · secondary NCT03429543
  • 0.1% vs 0.1% wk 432 · n 2951 · Phase 3 · secondary NCT01243424
  • -0.4% vs -0.3% 5 mg · wk 52 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 46 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.2% 5 mg · wk 40 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.4% 5 mg · wk 34 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 28 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.7% 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.5% 5 mg · wk 24 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.5% 5 mg · wk 20 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.6% 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.3% 5 mg · wk 16 · n 113 · Phase 3 · secondary NCT01087502
  • -0.4% vs -0.4% 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.1% 5 mg · wk 12 · n 113 · Phase 3 · secondary NCT01087502
  • -0.5% vs -0.1% 5 mg · wk 8 · n 113 · Phase 3 · secondary NCT01087502
  • -0.2% vs -0.2% 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.3% vs -0.1% 5 mg · wk 4 · n 113 · Phase 3 · secondary NCT01087502
  • -0.9% vs -0.7% 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.3% vs -0.7% 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.7% 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.7% 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.7% 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -0.8% vs -0.6% 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.1% vs -0.6% 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.2% vs -0.6% 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -0.7% vs -0.4% 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -0.9% vs -0.4% 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.0% vs -0.4% 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4% vs -0.2% 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -0.5% vs -0.2% 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -0.6% vs -0.2% 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -1.3% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 78 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 78 · n 111 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.3% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 66 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.3% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 66 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -1.4% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 113 · Phase 3 · secondary NCT00915772
  • -1.6% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 111 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.4% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -1.3% vs -1.2% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 113 · Phase 3 · secondary NCT00915772
  • -1.7% vs -1.2% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 111 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.2% vs -0.1% linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.3% vs -0.1% linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -1.0% vs -0.4% 5 mg · wk 24 · n 149 · Phase 4 · primary NCT02240680
  • -0.5% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · primary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · primary NCT01012037
  • -1.0% vs -1.0% 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · primary NCT01438814
  • -0.6% vs 0.3% 5 mg once daily · wk 12 · n 221 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 5 mg once daily · wk 6 · n 221 · Phase 2 · secondary NCT01012037
  • -0.5% vs 0.3% 2.5 mg twice daily · wk 12 · n 214 · Phase 2 · secondary NCT01012037
  • -0.3% vs 0.3% 2.5 mg twice daily · wk 6 · n 214 · Phase 2 · secondary NCT01012037
  • -0.8% vs -0.8% 5 mg once daily + metformin once daily · wk 8 · n 298 · Phase 4 · secondary NCT01438814
  • -0.3% vs -0.3% 5 mg once daily + metformin once daily · wk 2 · n 298 · Phase 4 · secondary NCT01438814
  • 7.6% vs 8% wk 12 · n 128 · Phase 4 · secondary NCT02004366
  • 6.6% vs 8% wk 12 · n 92 · Phase 4 · secondary NCT02004366
  • 7% vs 8% wk 12 · n 93 · Phase 4 · secondary NCT02004366
  • 8.6% vs 8% wk 12 · n 39 · Phase 4 · secondary NCT02004366

Body weight, change (kg)

Alogliptin
0.6 vs 0.6±0 vs placebo25 mg QD · wk 26 · n 124NCT00286429
111 other results
  • -0.2 vs 0.2 25 mg QD · wk 26 · n 125 · Phase 3 · secondary NCT00286455
  • -0.7 vs -0.7 25 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs 1.0 25 mg QD · wk 26 · n 189 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.4 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286442
  • 0.7 vs -0.2 25 mg QD · wk 26 · n 195 · Phase 3 · secondary NCT00286468
  • 0.5 vs 0.7 25 mg QD · wk 20 · n 124 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 25 mg QD · wk 20 · n 125 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.6 25 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 0.9 vs 0.9 25 mg QD · wk 20 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.4 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.3 25 mg QD · wk 20 · n 195 · Phase 3 · secondary NCT00286468
  • 0.3 vs 0.5 25 mg QD · wk 12 · n 123 · Phase 3 · secondary NCT00286429
  • 0.1 vs -0.3 25 mg QD · wk 12 · n 125 · Phase 3 · secondary NCT00286455
  • -0.6 vs -0.5 25 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 0.6 vs 0.6 25 mg QD · wk 12 · n 189 · Phase 3 · secondary NCT00286494
  • -0.6 vs -0.6 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286442
  • 0.4 vs -0.1 25 mg QD · wk 12 · n 194 · Phase 3 · secondary NCT00286468
  • 0.2 vs 0.4 25 mg QD · wk 8 · n 121 · Phase 3 · secondary NCT00286429
  • -0.0 vs -0.4 25 mg QD · wk 8 · n 123 · Phase 3 · secondary NCT00286455
  • -0.5 vs -0.1 25 mg · wk 8 · n 120 · Phase 3 · secondary NCT00328627
  • 0.4 vs 0.4 25 mg QD · wk 8 · n 186 · Phase 3 · secondary NCT00286494
  • -0.5 vs -0.1 25 mg QD · wk 8 · n 193 · Phase 3 · secondary NCT00286442
  • 0.3 vs -0.3 25 mg QD · wk 8 · n 188 · Phase 3 · secondary NCT00286468
  • 0.7 vs 0.6 12.5 mg QD · wk 26 · n 127 · Phase 3 · secondary NCT00286429
  • -0.1 vs 0.2 12.5 mg QD · wk 26 · n 126 · Phase 3 · secondary NCT00286455
  • -0.0 vs -0.7 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.5 vs 1.0 12.5 mg QD · wk 26 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 26 · n 206 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.2 12.5 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286468
  • 0.6 vs 0.7 12.5 mg QD · wk 20 · n 127 · Phase 3 · secondary NCT00286429
  • -0.2 vs -0.2 12.5 mg QD · wk 20 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.6 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 1.1 vs 0.9 12.5 mg QD · wk 20 · n 193 · Phase 3 · secondary NCT00286494
  • -0.4 vs -0.4 12.5 mg QD · wk 20 · n 205 · Phase 3 · secondary NCT00286442
  • 0.8 vs -0.3 12.5 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286468
  • 0.4 vs 0.5 12.5 mg QD · wk 12 · n 127 · Phase 3 · secondary NCT00286429
  • -0.4 vs -0.3 12.5 mg QD · wk 12 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.5 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs 0.6 12.5 mg QD · wk 12 · n 193 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.6 12.5 mg QD · wk 12 · n 205 · Phase 3 · secondary NCT00286442
  • 0.6 vs -0.1 12.5 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.4 12.5 mg QD · wk 8 · n 125 · Phase 3 · secondary NCT00286429
  • 0.0 vs -0.4 12.5 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286455
  • -0.1 vs -0.1 12.5 mg · wk 8 · n 119 · Phase 3 · secondary NCT00328627
  • 0.5 vs 0.4 12.5 mg QD · wk 8 · n 190 · Phase 3 · secondary NCT00286494
  • -0.3 vs -0.1 12.5 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286442
  • 0.5 vs -0.3 12.5 mg QD · wk 8 · n 194 · Phase 3 · secondary NCT00286468
  • 1.3 vs -0.7 25 mg + 15 mg · wk 26 · n 124 · Phase 3 · secondary NCT00328627
  • 2.1 vs -0.7 25 mg + 30 mg · wk 26 · n 123 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 25 mg + 45 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • 0.8 vs -0.6 25 mg + 15 mg · wk 20 · n 124 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 30 mg · wk 20 · n 123 · Phase 3 · secondary NCT00328627
  • 1.8 vs -0.6 25 mg + 45 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.5 25 mg + 15 mg · wk 12 · n 124 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.5 25 mg + 30 mg · wk 12 · n 123 · Phase 3 · secondary NCT00328627
  • 1.1 vs -0.5 25 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.1 25 mg + 15 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • 0.7 vs -0.1 25 mg + 30 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.1 25 mg + 45 mg · wk 8 · n 124 · Phase 3 · secondary NCT00328627
  • 1.3 vs -0.7 12.5 mg + 15 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.7 12.5 mg + 30 mg · wk 26 · n 125 · Phase 3 · secondary NCT00328627
  • 2.3 vs -0.7 12.5 mg + 45 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • 1.0 vs -0.6 12.5 mg + 15 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • 1.4 vs -0.6 12.5 mg + 30 mg · wk 20 · n 125 · Phase 3 · secondary NCT00328627
  • 1.9 vs -0.6 12.5 mg + 45 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • 0.2 vs -0.5 12.5 mg + 15 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • 0.6 vs -0.5 12.5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT00328627
  • 0.9 vs -0.5 12.5 mg + 45 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • 0.1 vs -0.1 12.5 mg + 15 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • 0.5 vs -0.1 12.5 mg + 30 mg · wk 8 · n 125 · Phase 3 · secondary NCT00328627
  • 0.4 vs -0.1 12.5 mg + 45 mg · wk 8 · n 121 · Phase 3 · secondary NCT00328627
  • -0.9 vs -1.6 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -0.8 vs -1.6 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.6 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -1.0 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -0.4 vs -1.0 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.1 vs -1.0 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs 0.9 25 mg · wk 26 · n 868 · Phase 3 · secondary NCT00856284
  • 0.7 vs 1.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 1.0 25 mg · wk 39 · n 868 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 25 mg · wk 12 · n 868 · Phase 3 · secondary NCT00856284
  • 0.3 vs 0.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • 1.1 vs 1.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • 0.3 vs 0.5 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • 0.2 vs 0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 52 · n 868 · Phase 3 · secondary NCT00856284
  • 1.1 vs 1.6 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs 0.9 25 mg · wk 65 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 78 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 91 · n 868 · Phase 3 · secondary NCT00856284
  • -0.9 vs 0.9 25 mg · wk 104 · n 868 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 1.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs 0.7 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs 0.9 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs 0.9 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.7 vs 0.9 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 2.2 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -0.5 vs 1.6 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs 1.0 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.3 vs 0.6 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 3.1 vs 2.2 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • 2.4 vs 1.6 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • 1.4 vs 1.0 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • 0.8 vs 0.6 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • 2.5 vs 2.2 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • 1.9 vs 1.6 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • 1.2 vs 1.0 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • 0.7 vs 0.6 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
Linagliptin
1.4 vs -0.0+1.5 vs placebo5 mg · wk 26 · n 49NCT03429543
4 other results
  • -2.5 vs -0.3 25 mg + 5 mg · wk 24 · n 110 · Phase 3 · secondary NCT01734785
  • -3.1 vs -0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • 2.7 vs -0.0 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • -0.4 vs -1.1 5 mg once daily + metformin once daily · wk 14 · n 287 · Phase 4 · secondary NCT01438814

HbA1c below 7%

Alogliptin
63.3% vs 30%+33.3 vs placebowk 16 · n 90NCT01289119
2 other results
  • 55.1% vs 30% wk 16 · n 98 · Phase 3 · secondary NCT01289119
  • 61.7% vs 30% wk 16 · n 60 · Phase 3 · secondary NCT01289119
Linagliptin
26.9% vs 24.5%+2.4 vs placebo5 mg · wk 26 · n 52NCT03429543
7 other results
  • 13.9% vs 8.2% wk 24 · n 101 · Phase 3 · secondary NCT02897349
  • 16.7% vs 24.5% 5 mg · wk 26 · n 6 · Phase 3 · secondary NCT03429543
  • 43.6% vs 50% 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 72.1% vs 50% 2.5 mg / 500 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 77.1% vs 50% 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • 33% vs 10% 5 mg once daily · wk 12 · n 215 · Phase 2 · secondary NCT01012037
  • 34% vs 10% 2.5 mg twice daily · wk 12 · n 206 · Phase 2 · secondary NCT01012037

Fasting plasma glucose, change

Alogliptin
-0.7 vs 0.3−1 vs placebo25 mg QD · wk 26 · n 128NCT00286429
351 other results
  • -0.9 vs 0.6 25 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286455
  • -0.3 vs 0.7 25 mg QD · wk 26 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.4 25 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 25 mg QD · wk 26 · n 197 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 25 mg QD · wk 26 · n 204 · Phase 3 · secondary NCT00286442
  • -0.5 vs 0.1 25 mg QD · wk 26 · n 198 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.5 25 mg QD · wk 20 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.4 25 mg QD · wk 20 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.5 25 mg QD · wk 20 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.4 25 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 25 mg QD · wk 20 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs -0.0 25 mg QD · wk 20 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.0 25 mg QD · wk 20 · n 198 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 25 mg QD · wk 16 · n 128 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.3 25 mg QD · wk 16 · n 129 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.6 25 mg QD · wk 16 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.1 25 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.5 25 mg QD · wk 16 · n 197 · Phase 3 · secondary NCT00286494
  • -0.8 vs 0.1 25 mg QD · wk 16 · n 204 · Phase 3 · secondary NCT00286442
  • -0.7 vs -0.4 25 mg QD · wk 16 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs -0.1 25 mg QD · wk 12 · n 128 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 12 · n 129 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.6 25 mg QD · wk 12 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.6 25 mg QD · wk 12 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 12 · n 204 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 25 mg QD · wk 12 · n 198 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 25 mg QD · wk 8 · n 126 · Phase 3 · secondary NCT00286429
  • -1.1 vs 0.1 25 mg QD · wk 8 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 8 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -1.5 vs -0.3 25 mg QD · wk 8 · n 197 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 25 mg QD · wk 8 · n 204 · Phase 3 · secondary NCT00286442
  • -1.0 vs -0.2 25 mg QD · wk 8 · n 198 · Phase 3 · secondary NCT00286468
  • -0.7 vs 0.3 25 mg QD · wk 4 · n 120 · Phase 3 · secondary NCT00286429
  • -1.2 vs 0.2 25 mg QD · wk 4 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.4 25 mg QD · wk 4 · n 112 · Phase 3 · secondary NCT01023581
  • -1.3 vs 0.2 25 mg · wk 4 · n 125 · Phase 3 · secondary NCT00328627
  • -1.4 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 25 mg QD · wk 4 · n 204 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.2 25 mg QD · wk 4 · n 197 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.1 25 mg QD · wk 2 · n 119 · Phase 3 · secondary NCT00286429
  • -1.0 vs 0.2 25 mg QD · wk 2 · n 126 · Phase 3 · secondary NCT00286455
  • -0.4 vs 0.3 25 mg QD · wk 2 · n 112 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 25 mg · wk 2 · n 125 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 193 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 25 mg QD · wk 2 · n 199 · Phase 3 · secondary NCT00286442
  • -1.2 vs -0.1 25 mg QD · wk 2 · n 194 · Phase 3 · secondary NCT00286468
  • -0.6 vs 0.3 25 mg QD · wk 1 · n 111 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 25 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286455
  • -0.2 vs 0.3 25 mg QD · wk 1 · n 112 · Phase 3 · secondary NCT01023581
  • -1.0 vs 0.1 25 mg · wk 1 · n 117 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.1 25 mg QD · wk 1 · n 171 · Phase 3 · secondary NCT00286494
  • -0.7 vs -0.0 25 mg QD · wk 1 · n 186 · Phase 3 · secondary NCT00286442
  • -1.1 vs 0.0 25 mg QD · wk 1 · n 185 · Phase 3 · secondary NCT00286468
  • 0.1 vs 0.3 12.5 mg QD · wk 26 · n 131 · Phase 3 · secondary NCT00286429
  • -0.6 vs 0.6 12.5 mg QD · wk 26 · n 132 · Phase 3 · secondary NCT00286455
  • -0.5 vs 0.7 12.5 mg BID · wk 26 · n 110 · Phase 3 · secondary NCT01023581
  • -0.7 vs 0.4 12.5 mg · wk 26 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.3 12.5 mg QD · wk 26 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0 12.5 mg QD · wk 26 · n 211 · Phase 3 · secondary NCT00286442
  • -0.3 vs 0.1 12.5 mg QD · wk 26 · n 201 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.5 12.5 mg QD · wk 20 · n 131 · Phase 3 · secondary NCT00286429
  • -0.7 vs 0.4 12.5 mg QD · wk 20 · n 132 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.5 12.5 mg BID · wk 20 · n 110 · Phase 3 · secondary NCT01023581
  • -0.5 vs 0.4 12.5 mg · wk 20 · n 122 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.4 12.5 mg QD · wk 20 · n 196 · Phase 3 · secondary NCT00286494
  • -1 vs -0.0 12.5 mg QD · wk 20 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.0 12.5 mg QD · wk 20 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 16 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.3 12.5 mg QD · wk 16 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 16 · n 110 · Phase 3 · secondary NCT01023581
  • -0.9 vs 0.1 12.5 mg · wk 16 · n 122 · Phase 3 · secondary NCT00328627
  • -1.0 vs -0.5 12.5 mg QD · wk 16 · n 196 · Phase 3 · secondary NCT00286494
  • -1.0 vs 0.1 12.5 mg QD · wk 16 · n 211 · Phase 3 · secondary NCT00286442
  • -0.5 vs -0.4 12.5 mg QD · wk 16 · n 201 · Phase 3 · secondary NCT00286468
  • -0.3 vs -0.1 12.5 mg QD · wk 12 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 12 · n 132 · Phase 3 · secondary NCT00286455
  • -0.8 vs 0.6 12.5 mg BID · wk 12 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 12 · n 122 · Phase 3 · secondary NCT00328627
  • -1.1 vs -0.6 12.5 mg QD · wk 12 · n 196 · Phase 3 · secondary NCT00286494
  • -0.9 vs 0.0 12.5 mg QD · wk 12 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 201 · Phase 3 · secondary NCT00286468
  • -0.8 vs 0.3 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.1 12.5 mg QD · wk 8 · n 131 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.4 12.5 mg BID · wk 8 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.3 12.5 mg · wk 8 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.3 12.5 mg QD · wk 8 · n 196 · Phase 3 · secondary NCT00286494
  • -1.1 vs 0.0 12.5 mg QD · wk 8 · n 211 · Phase 3 · secondary NCT00286442
  • -1.1 vs -0.2 12.5 mg QD · wk 8 · n 200 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 4 · n 128 · Phase 3 · secondary NCT00286429
  • -0.9 vs 0.2 12.5 mg QD · wk 4 · n 131 · Phase 3 · secondary NCT00286455
  • -0.9 vs 0.4 12.5 mg BID · wk 4 · n 110 · Phase 3 · secondary NCT01023581
  • -1.1 vs 0.2 12.5 mg · wk 4 · n 122 · Phase 3 · secondary NCT00328627
  • -1.3 vs -0.2 12.5 mg QD · wk 4 · n 194 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 4 · n 211 · Phase 3 · secondary NCT00286442
  • -0.8 vs -0.2 12.5 mg QD · wk 4 · n 198 · Phase 3 · secondary NCT00286468
  • -0.2 vs 0.1 12.5 mg QD · wk 2 · n 127 · Phase 3 · secondary NCT00286429
  • -0.8 vs 0.2 12.5 mg QD · wk 2 · n 129 · Phase 3 · secondary NCT00286455
  • -0.6 vs 0.3 12.5 mg BID · wk 2 · n 110 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.3 12.5 mg · wk 2 · n 120 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.1 12.5 mg QD · wk 2 · n 189 · Phase 3 · secondary NCT00286494
  • -1.0 vs -0.0 12.5 mg QD · wk 2 · n 208 · Phase 3 · secondary NCT00286442
  • -0.9 vs -0.1 12.5 mg QD · wk 2 · n 197 · Phase 3 · secondary NCT00286468
  • -0.3 vs 0.3 12.5 mg QD · wk 1 · n 121 · Phase 3 · secondary NCT00286429
  • -0.5 vs 0.3 12.5 mg QD · wk 1 · n 120 · Phase 3 · secondary NCT00286455
  • -0.7 vs 0.3 12.5 mg BID · wk 1 · n 110 · Phase 3 · secondary NCT01023581
  • -0.8 vs 0.1 12.5 mg · wk 1 · n 114 · Phase 3 · secondary NCT00328627
  • -0.8 vs -0.1 12.5 mg QD · wk 1 · n 176 · Phase 3 · secondary NCT00286494
  • -0.8 vs -0.0 12.5 mg QD · wk 1 · n 193 · Phase 3 · secondary NCT00286442
  • -0.7 vs 0.0 12.5 mg QD · wk 1 · n 189 · Phase 3 · secondary NCT00286468
  • -2.1 vs 0.4 25 mg + 15 mg · wk 26 · n 130 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 25 mg + 30 mg · wk 26 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 26 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.4 25 mg + 15 mg · wk 20 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.4 25 mg + 30 mg · wk 20 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 25 mg + 45 mg · wk 20 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.1 25 mg + 15 mg · wk 16 · n 130 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.1 25 mg + 30 mg · wk 16 · n 126 · Phase 3 · secondary NCT00328627
  • -3.0 vs 0.1 25 mg + 45 mg · wk 16 · n 127 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 25 mg + 15 mg · wk 12 · n 130 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 25 mg + 30 mg · wk 12 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.2 25 mg + 45 mg · wk 12 · n 127 · Phase 3 · secondary NCT00328627
  • -2.2 vs 0.3 25 mg + 15 mg · wk 8 · n 130 · Phase 3 · secondary NCT00328627
  • -2.5 vs 0.3 25 mg + 30 mg · wk 8 · n 126 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.3 25 mg + 45 mg · wk 8 · n 127 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 25 mg + 15 mg · wk 4 · n 130 · Phase 3 · secondary NCT00328627
  • -2 vs 0.2 25 mg + 30 mg · wk 4 · n 126 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.2 25 mg + 45 mg · wk 4 · n 127 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 15 mg · wk 2 · n 129 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 25 mg + 30 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 25 mg + 45 mg · wk 2 · n 126 · Phase 3 · secondary NCT00328627
  • -1.2 vs 0.1 25 mg + 15 mg · wk 1 · n 123 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 25 mg + 30 mg · wk 1 · n 118 · Phase 3 · secondary NCT00328627
  • -1.4 vs 0.1 25 mg + 45 mg · wk 1 · n 113 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.7 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 26 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.7 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 26 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.4 12.5 mg + 15 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 26 · n 129 · Phase 3 · secondary NCT00328627
  • -2.9 vs 0.4 12.5 mg + 45 mg · wk 26 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.5 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 20 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.5 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 20 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 12.5 mg + 15 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.4 12.5 mg + 30 mg · wk 20 · n 129 · Phase 3 · secondary NCT00328627
  • -2.6 vs 0.4 12.5 mg + 45 mg · wk 20 · n 128 · Phase 3 · secondary NCT00328627
  • -2.0 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 16 · n 106 · Phase 3 · secondary NCT01023581
  • -2.6 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 16 · n 114 · Phase 3 · secondary NCT01023581
  • -2.3 vs 0.1 12.5 mg + 15 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.1 12.5 mg + 30 mg · wk 16 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.1 12.5 mg + 45 mg · wk 16 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.6 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 12 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.6 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 12 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.2 12.5 mg + 15 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.2 12.5 mg + 30 mg · wk 12 · n 129 · Phase 3 · secondary NCT00328627
  • -2.7 vs 0.2 12.5 mg + 45 mg · wk 12 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 8 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 8 · n 114 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 12.5 mg + 15 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.3 vs 0.3 12.5 mg + 30 mg · wk 8 · n 129 · Phase 3 · secondary NCT00328627
  • -2.4 vs 0.3 12.5 mg + 45 mg · wk 8 · n 128 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.4 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 4 · n 106 · Phase 3 · secondary NCT01023581
  • -2.5 vs 0.4 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 4 · n 114 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.2 12.5 mg + 15 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 30 mg · wk 4 · n 129 · Phase 3 · secondary NCT00328627
  • -2.1 vs 0.2 12.5 mg + 45 mg · wk 4 · n 128 · Phase 3 · secondary NCT00328627
  • -1.9 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 2 · n 106 · Phase 3 · secondary NCT01023581
  • -2.4 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 2 · n 114 · Phase 3 · secondary NCT01023581
  • -1.7 vs 0.3 12.5 mg + 15 mg · wk 2 · n 127 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 30 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.7 vs 0.3 12.5 mg + 45 mg · wk 2 · n 128 · Phase 3 · secondary NCT00328627
  • -1.8 vs 0.3 alogliptin 12.5 mg BID + metformin 500 mg BID · wk 1 · n 106 · Phase 3 · secondary NCT01023581
  • -2.0 vs 0.3 alogliptin 12.5 mg BID + metformin 1000 mg BID · wk 1 · n 114 · Phase 3 · secondary NCT01023581
  • -1.2 vs 0.1 12.5 mg + 15 mg · wk 1 · n 121 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 30 mg · wk 1 · n 119 · Phase 3 · secondary NCT00328627
  • -1.3 vs 0.1 12.5 mg + 45 mg · wk 1 · n 115 · Phase 3 · secondary NCT00328627
  • -1.2 vs -0.3 wk 16 · n 92 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.3 wk 16 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs 0.7 25 mg QD · wk 16 · n 25 · Phase 3 · secondary NCT00655863
  • -0.9 vs 0.3 25 mg QD · wk 8 · n 25 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.2 25 mg QD · wk 4 · n 25 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.7 25 mg QD + 30 mg QD · wk 16 · n 22 · Phase 3 · secondary NCT00655863
  • -2.1 vs 0.3 25 mg QD + 30 mg QD · wk 8 · n 22 · Phase 3 · secondary NCT00655863
  • -2.2 vs -0.2 25 mg QD + 30 mg QD · wk 4 · n 22 · Phase 3 · secondary NCT00655863
  • -1.1 vs -0.3 wk 16 · n 61 · Phase 3 · secondary NCT01289119
  • -1.1 vs -0.4 wk 12 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.4 wk 12 · n 99 · Phase 3 · secondary NCT01289119
  • -1.2 vs -0.4 wk 12 · n 61 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 8 · n 92 · Phase 3 · secondary NCT01289119
  • -1.3 vs -0.3 wk 8 · n 99 · Phase 3 · secondary NCT01289119
  • -0.9 vs -0.3 wk 8 · n 61 · Phase 3 · secondary NCT01289119
  • -0.7 vs -0.3 wk 4 · n 92 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 99 · Phase 3 · secondary NCT01289119
  • -1.0 vs -0.3 wk 4 · n 61 · Phase 3 · secondary NCT01289119
  • -0.4 vs 0.1 25 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.2 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 52 · n 404 · Phase 3 · secondary NCT00432276
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 42 · n 404 · Phase 3 · secondary NCT00432276
  • -0.5 vs -0.0 25 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 25 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.8 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 34 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.2 25 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.3 25 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 26 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.3 25 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 20 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 16 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 25 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 12 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.5 25 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -1.1 vs -0.3 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 8 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.6 25 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -1.0 vs -0.1 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 4 · n 404 · Phase 3 · secondary NCT00432276
  • -0.6 vs -0.4 25 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.9 vs -0.0 Alogliptin 25 mg; Pioglitazone 30 mg; Metformin · wk 2 · n 404 · Phase 3 · secondary NCT00432276
  • -0.2 vs 0.3 25 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -0.3 vs 0.1 12.5 mg · wk 52 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.0 12.5 mg · wk 39 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.1 12.5 mg · wk 65 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.2 12.5 mg · wk 26 · n 867 · Phase 3 · secondary NCT00856284
  • -0.2 vs 0.3 12.5 mg · wk 78 · n 867 · Phase 3 · secondary NCT00856284
  • -0.4 vs -0.3 12.5 mg · wk 20 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.4 12.5 mg · wk 16 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 91 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.5 12.5 mg · wk 12 · n 867 · Phase 3 · secondary NCT00856284
  • -0.5 vs -0.5 12.5 mg · wk 8 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.6 12.5 mg · wk 4 · n 867 · Phase 3 · secondary NCT00856284
  • -0.6 vs -0.4 12.5 mg · wk 2 · n 867 · Phase 3 · secondary NCT00856284
  • -0.1 vs 0.3 12.5 mg · wk 104 · n 867 · Phase 3 · secondary NCT00856284
  • -1.4 vs -2.1 25 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.3 25 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -2.3 25 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.4 25 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -1.6 vs -2.1 25 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.5 vs -1.8 25 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs -0.8 25 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -0.8 vs -0.4 25 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -1.1 vs -0.3 12.5 mg QD · wk 12 · n 76 · Phase 2/3 · secondary NCT01263483
  • -1.1 vs -0.1 12.5 mg QD · wk 8 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.0 12.5 mg QD · wk 4 · n 76 · Phase 2/3 · secondary NCT01263483
  • -0.9 vs -0.2 12.5 mg QD · wk 2 · n 76 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 26 · n 164 · Phase 3 · secondary NCT00395512
  • -3 vs -2.3 25 mg + 30 mg · wk 20 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.3 25 mg + 30 mg · wk 16 · n 164 · Phase 3 · secondary NCT00395512
  • -2.9 vs -2.4 25 mg + 30 mg · wk 12 · n 164 · Phase 3 · secondary NCT00395512
  • -0.9 vs 0.3 25 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.1 vs -0.1 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.3 25 mg QD + 0.2 mg TID · wk 12 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.8 vs -2.1 25 mg + 30 mg · wk 8 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.2 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.2 vs -0.1 25 mg QD + 0.2 mg TID · wk 8 · n 79 · Phase 2/3 · secondary NCT01263483
  • -2.3 vs -1.8 25 mg + 30 mg · wk 4 · n 164 · Phase 3 · secondary NCT00395512
  • -1.3 vs 0.1 25 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -1.0 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.0 25 mg QD + 0.2 mg TID · wk 4 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.9 vs -0.8 25 mg + 30 mg · wk 2 · n 164 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 25 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 113 · Phase 2/3 · secondary NCT01318070
  • -1.0 vs -0.2 25 mg QD + 0.2 mg TID · wk 2 · n 79 · Phase 2/3 · secondary NCT01263483
  • -1.5 vs -0.4 25 mg + 30 mg · wk 1 · n 164 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 26 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 20 · n 163 · Phase 3 · secondary NCT00395512
  • -2.6 vs -2.3 12.5 mg + 30 mg · wk 16 · n 163 · Phase 3 · secondary NCT00395512
  • -2.7 vs -2.4 12.5 mg + 30 mg · wk 12 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 12 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.1 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 12 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.7 vs -2.1 12.5 mg + 30 mg · wk 8 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.3 12.5 mg QD · wk 8 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.9 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 8 · n 111 · Phase 2/3 · secondary NCT01318070
  • -2.2 vs -1.8 12.5 mg + 30 mg · wk 4 · n 163 · Phase 3 · secondary NCT00395512
  • -1.2 vs 0.1 12.5 mg QD · wk 4 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.8 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 4 · n 111 · Phase 2/3 · secondary NCT01318070
  • -1.7 vs -0.8 12.5 mg + 30 mg · wk 2 · n 163 · Phase 3 · secondary NCT00395512
  • -1.0 vs 0.0 12.5 mg QD · wk 2 · n 104 · Phase 2/3 · secondary NCT01318083
  • -0.7 vs -0.2 alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD · wk 2 · n 110 · Phase 2/3 · secondary NCT01318070
  • -1.3 vs -0.4 12.5 mg + 30 mg · wk 1 · n 163 · Phase 3 · secondary NCT00395512
  • -1.5 vs 0.5 25 mg QD · wk 12.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.0 vs 0.3 25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.4 vs 0.3 25 mg QD · wk 6.14 · n 45 · Phase 2 · secondary NCT00755846
  • -1.1 vs 0.5 25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.3 vs 0.5 12.5 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.8 vs 0.3 12.5 mg QD · wk 12 · n 84 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 12.5 mg QD · wk 8 · n 84 · Phase 2 · secondary NCT01263470
  • -0.6 vs 0.3 12.5 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -1.2 vs 0.5 12.5 mg QD · wk 4 · n 84 · Phase 2 · secondary NCT01263470
  • -0.9 vs 0.1 12.5 mg QD · wk 2 · n 84 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.5 100 mg QD · wk 12.14 · n 44 · Phase 2 · secondary NCT00755846
  • -1.4 vs 0.3 100 mg QD · wk 6.14 · n 44 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 50 mg QD · wk 12.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.3 50 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -1.3 vs 0.3 50 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -1.0 vs 0.3 50 mg QD · wk 6.14 · n 43 · Phase 2 · secondary NCT00755846
  • -1.3 vs 0.5 50 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs 0.1 50 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.5 6.25 mg QD · wk 12.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.5 vs 0.3 6.25 mg QD · wk 12 · n 79 · Phase 2 · secondary NCT01263470
  • -0.7 vs 0.3 6.25 mg QD · wk 8 · n 79 · Phase 2 · secondary NCT01263470
  • -0.4 vs 0.3 6.25 mg QD · wk 6.14 · n 42 · Phase 2 · secondary NCT00755846
  • -0.9 vs 0.5 6.25 mg QD · wk 4 · n 79 · Phase 2 · secondary NCT01263470
  • -0.8 vs 0.1 6.25 mg QD · wk 2 · n 79 · Phase 2 · secondary NCT01263470
  • -1.2 vs -0.7 25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 25 mg QD · wk 44 · n 63 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 25 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 32 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.4 25 mg QD · wk 28 · n 87 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 25 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 25 mg QD · wk 20 · n 88 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 25 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.2 25 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 25 mg QD · n 96 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.7 12.5 mg QD · wk 52 · n 59 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.8 12.5 mg QD · wk 48 · n 60 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.8 12.5 mg QD · wk 44 · n 61 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 12.5 mg QD · wk 40 · n 79 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 12.5 mg QD · wk 36 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 32 · n 81 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.4 12.5 mg QD · wk 28 · n 82 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.5 12.5 mg QD · wk 24 · n 84 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.3 12.5 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.4 12.5 mg QD · wk 16 · n 89 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.2 12.5 mg QD · wk 12 · n 97 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.5 12.5 mg QD · n 101 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.7 50 mg QD · wk 52 · n 68 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 48 · n 69 · Phase 2 · secondary NCT01263496
  • -1.4 vs -0.8 50 mg QD · wk 44 · n 69 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.8 50 mg QD · wk 40 · n 84 · Phase 2 · secondary NCT01263496
  • -1.2 vs -0.5 50 mg QD · wk 36 · n 84 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 32 · n 85 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.4 50 mg QD · wk 28 · n 86 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.5 50 mg QD · wk 24 · n 89 · Phase 2 · secondary NCT01263496
  • -1.1 vs -0.3 50 mg QD · wk 20 · n 90 · Phase 2 · secondary NCT01263496
  • -1.0 vs -0.4 50 mg QD · wk 16 · n 97 · Phase 2 · secondary NCT01263496
  • -1.3 vs -0.2 50 mg QD · wk 12 · n 94 · Phase 2 · secondary NCT01263496
  • -1.5 vs -0.5 50 mg QD · n 97 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.7 6.25 mg QD · wk 52 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 48 · n 62 · Phase 2 · secondary NCT01263496
  • -0.9 vs -0.8 6.25 mg QD · wk 44 · n 65 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.8 6.25 mg QD · wk 40 · n 81 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 36 · n 81 · Phase 2 · secondary NCT01263496
  • -0.8 vs -0.5 6.25 mg QD · wk 32 · n 84 · Phase 2 · secondary NCT01263496
  • -0.5 vs -0.4 6.25 mg QD · wk 28 · n 85 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.3 6.25 mg QD · wk 20 · n 87 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.4 6.25 mg QD · wk 16 · n 88 · Phase 2 · secondary NCT01263496
  • -0.7 vs -0.2 6.25 mg QD · wk 12 · n 93 · Phase 2 · secondary NCT01263496
  • -0.6 vs -0.5 6.25 mg QD · n 96 · Phase 2 · secondary NCT01263496
Linagliptin
-0.1 vs 0.0−0.2 vs placebo5 mg · wk 52 · n 614NCT00954447
95 other results
  • -0.4 vs -0.2 5 mg · wk 40 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs -0.1 5 mg · wk 32 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.3 5 mg · wk 24 · n 614 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.2 5 mg · wk 6 · n 606 · Phase 3 · secondary NCT00954447
  • -0.3 vs 0.5 wk 24 · n 739 · Phase 3 · secondary NCT00602472
  • -0.5 vs 0.1 5 mg · wk 24 · n 196 · Phase 3 · secondary NCT01214239
  • -0.6 vs -0.1 5 mg once daily · wk 24 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs 0 5 mg · wk 24 · n 606 · Phase 3 · secondary NCT00954447
  • -0.2 vs 0.1 5 mg · wk 18 · n 606 · Phase 3 · secondary NCT00954447
  • -0.6 vs 0.0 5 mg tablet · wk 24 · n 175 · Phase 3 · secondary NCT00996658
  • -0.6 vs 0.6 wk 24 · n 495 · Phase 3 · secondary NCT00601250
  • -0.3 vs 0.4 wk 18 · n 739 · Phase 3 · secondary NCT00602472
  • -0.6 vs 0.6 wk 18 · n 495 · Phase 3 · secondary NCT00601250
  • -0.5 vs 0.3 wk 12 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.2 wk 12 · n 495 · Phase 3 · secondary NCT00601250
  • -0.6 vs 0.3 wk 6 · n 739 · Phase 3 · secondary NCT00602472
  • -0.7 vs 0.3 wk 6 · n 495 · Phase 3 · secondary NCT00601250
  • -1.3 vs -0.6 5 mg · wk 24 · n 95 · Phase 3 · secondary NCT01194830
  • -0.6 vs 0.6 5 mg · wk 24 · n 156 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 18 · n 196 · Phase 3 · secondary NCT01214239
  • -0.7 vs -0.1 5 mg once daily · wk 18 · n 203 · Phase 3 · secondary NCT01215097
  • -0.5 vs -0.1 5 mg tablet · wk 18 · n 175 · Phase 3 · secondary NCT00996658
  • -0.7 vs 0.5 5 mg · wk 18 · n 145 · Phase 3 · secondary NCT01084005
  • -0.6 vs -0.1 5 mg · wk 12 · n 196 · Phase 3 · secondary NCT01214239
  • -0.8 vs -0.3 5 mg once daily · wk 12 · n 203 · Phase 3 · secondary NCT01215097
  • -0.4 vs -0.0 5 mg · wk 12 · n 606 · Phase 3 · secondary NCT00954447
  • -0.4 vs 0.2 5 mg tablet · wk 12 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.4 5 mg · wk 12 · n 148 · Phase 3 · secondary NCT01084005
  • -0.7 vs -0.0 5 mg · wk 6 · n 196 · Phase 3 · secondary NCT01214239
  • -0.9 vs 0.3 5 mg once daily · wk 6 · n 203 · Phase 3 · secondary NCT01215097
  • -0.2 vs 0.7 5 mg tablet · wk 6 · n 175 · Phase 3 · secondary NCT00996658
  • -0.8 vs 0.3 5 mg · wk 6 · n 153 · Phase 3 · secondary NCT01084005
  • -1.8 vs 0.3 25 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.5 vs 0.3 10 mg + 5 mg · wk 24 · n 109 · Phase 3 · secondary NCT01734785
  • -1.8 vs -1.0 wk 24 · n 243 · Phase 3 · secondary NCT00641043
  • -0.5 vs 0.8 wk 24 · n 318 · Phase 3 · secondary NCT00621140
  • -1.8 vs -1.1 wk 18 · n 243 · Phase 3 · secondary NCT00641043
  • -0.4 vs 0.7 wk 18 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -1.1 wk 12 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.6 wk 12 · n 318 · Phase 3 · secondary NCT00621140
  • -1.9 vs -0.9 wk 6 · n 243 · Phase 3 · secondary NCT00641043
  • -0.6 vs 0.4 wk 6 · n 318 · Phase 3 · secondary NCT00621140
  • 0.2 vs -0.2 5 mg · wk 52 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.1 5 mg · wk 46 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.0 5 mg · wk 40 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -0.6 5 mg · wk 34 · n 112 · Phase 3 · secondary NCT01087502
  • -0.1 vs -1.6 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • 0 vs -1.4 5 mg · wk 30 · n 130 · Phase 3 · secondary NCT01183013
  • -0.5 vs -0.5 5 mg · wk 28 · n 112 · Phase 3 · secondary NCT01087502
  • -0.8 vs -1.7 5 mg QD · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.3 vs -1.2 5 mg · wk 24 · n 130 · Phase 3 · secondary NCT01183013
  • -0.7 vs -0.5 5 mg · wk 24 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs -0.5 5 mg · wk 20 · n 112 · Phase 3 · secondary NCT01087502
  • -0.4 vs -1.1 5 mg · wk 18 · n 130 · Phase 3 · secondary NCT01183013
  • -0.4 vs -1.2 5 mg · wk 12 · n 130 · Phase 3 · secondary NCT01183013
  • 0.0 vs 0.5 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.3 vs 0.3 5 mg · wk 12 · n 112 · Phase 3 · secondary NCT01087502
  • -0.6 vs 0.5 5 mg · wk 8 · n 112 · Phase 3 · secondary NCT01087502
  • -0.2 vs -0.9 5 mg · wk 6 · n 130 · Phase 3 · secondary NCT01183013
  • -0.6 vs 0.5 5 mg · wk 4 · n 112 · Phase 3 · secondary NCT01087502
  • -1.1 vs -1.6 5 mg + 15 mg · wk 30 · n 119 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.6 5 mg + 30 mg · wk 30 · n 123 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.6 5 mg + 45 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1 vs -1.4 5 mg + 15 mg · wk 30 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -1.4 5 mg + 30 mg · wk 30 · n 125 · Phase 3 · secondary NCT01183013
  • -1.9 vs -1.4 5 mg + 45 mg · wk 30 · n 126 · Phase 3 · secondary NCT01183013
  • -0.9 vs -1.2 5 mg + 15 mg · wk 24 · n 120 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 30 mg · wk 24 · n 125 · Phase 3 · secondary NCT01183013
  • -1.8 vs -1.2 5 mg + 45 mg · wk 24 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -1.1 5 mg + 15 mg · wk 18 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 30 mg · wk 18 · n 125 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.1 5 mg + 45 mg · wk 18 · n 126 · Phase 3 · secondary NCT01183013
  • -1 vs -1.2 5 mg + 15 mg · wk 12 · n 120 · Phase 3 · secondary NCT01183013
  • -1.7 vs -1.2 5 mg + 30 mg · wk 12 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -1.2 5 mg + 45 mg · wk 12 · n 126 · Phase 3 · secondary NCT01183013
  • -1.1 vs -0.9 5 mg + 15 mg · wk 6 · n 120 · Phase 3 · secondary NCT01183013
  • -1.5 vs -0.9 5 mg + 30 mg · wk 6 · n 125 · Phase 3 · secondary NCT01183013
  • -1.6 vs -0.9 5 mg + 45 mg · wk 6 · n 126 · Phase 3 · secondary NCT01183013
  • -0.4 vs -0.3 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 54 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.3 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 54 · n 171 · Phase 3 · secondary NCT00915772
  • -0.5 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 42 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 42 · n 171 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 30 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.4 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 30 · n 171 · Phase 3 · secondary NCT00915772
  • -2.2 vs -1.7 2.5 mg / 500 mg BID · wk 24 · n 142 · Phase 3 · secondary NCT01708902
  • -2.6 vs -1.7 2.5 mg / 1000 mg BID · wk 24 · n 140 · Phase 3 · secondary NCT01708902
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 18 · n 225 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.1 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 18 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 6 · n 225 · Phase 3 · secondary NCT00915772
  • -0.8 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 6 · n 171 · Phase 3 · secondary NCT00915772
  • -0.7 vs -0.2 linagliptin 2.5 mg bid + metformin 500 mg bid · wk 2 · n 225 · Phase 3 · secondary NCT00915772
  • -0.6 vs -0.2 linagliptin 2.5 mg bid + metformin 1000 mg bid · wk 2 · n 171 · Phase 3 · secondary NCT00915772
  • -1.2 vs -0.2 5 mg once daily · wk 12 · n 213 · Phase 2 · secondary NCT01012037
  • -0.9 vs -0.2 2.5 mg twice daily · wk 12 · n 203 · Phase 2 · secondary NCT01012037
  • -1.4 vs -1.5 5 mg once daily + metformin once daily · wk 14 · n 298 · Phase 4 · secondary NCT01438814

3-point MACE (% with event)

Alogliptin
11.3% vs 11.8%−0.5 vs placebon 2701NCT00968708
Linagliptin
20.7% vs 21.2%vs Glimepiridewk 432 · n 3023NCT01243424
2 other results
  • 11.8% vs 12% wk 432 · n 3023 · Phase 3 · secondary NCT01243424
  • 12.4% vs 12.1% n 3494 · Phase 4 · primary NCT01897532
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
11 other shared endpoints and safety

Coverage. Alogliptin: 15 of 15 rows · Linagliptin: 15 of 15 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAlogliptin
Rows use multiple source trials
Linagliptin
Rows use multiple source trials
Fasting Plasma Glucose
absolute change · mmol/L
No placebo or comparator arm
-0.87 mmol/L @ 24wk*Alogliptin 25 mg QD and Voglibose 0.2 mg TIDa,b,c
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -15.6 mg/dL as posted
show 3 more doses
-1.29 mmol/L*Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -23.3 mg/dL as posted
-0.77 mmol/L @ 24wk*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -13.8 mg/dL as posted
-0.97 mmol/L*Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination · converted to mmol/L from -17.5 mg/dL as posted
-1.68 mmol/L @ 24wk*5 mga,b,c
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.2 mg/dL as posted
show 3 more doses
-1.67 mmol/L @ 24wk*5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence · converted to mmol/L from -30.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
-2.61 mmol/L @ 24wk*5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination · converted to mmol/L from -47.1 mg/dL as posted
Glycemic Rescue
responder rate · % of participants
12.8% (n=125) vs 32.8% (n=125) placebo25 mga,c,d
NCT00328627 · Phase 3 · registry result, not featured evidence
show 7 more doses
14.5% (n=124) vs 32.8% (n=125) placebo12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9% (n=129) vs 32.8% (n=125) placebo25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.9% (n=123) vs 32.8% (n=125) placebo25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.6% (n=125) vs 32.8% (n=125) placebo25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.7% (n=129) vs 32.8% (n=125) placebo12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.8% (n=126) vs 32.8% (n=125) placebo12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.4% (n=127) vs 32.8% (n=125) placebo12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
7.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk5 mg QDa,c,d
NCT01708902 · Phase 3 · registry result, not featured evidence
show 2 more doses
2.1% (n=141) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4% (n=142) vs 2.1% (n=144) Metformin @ 24wk2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
HbA1c
absolute change · percentage points
No placebo or comparator arm
-0.7% (n=145) @ 24wk25 mg QD and 1-6 mg QD or BIDa,b,c
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
show 3 more doses
-0.78% (n=134) @ 24wk25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.59% (n=137) @ 24wk12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-0.68% (n=135) @ 24wk12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
-2.02% (n=113) @ 24wk5 mga,b,c
NCT01512979 · Phase 4 · registry result, not featured evidence
show 3 more doses
-2.01% (n=113) @ 24wk5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
-2.81% (n=132) @ 24wk5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
HbA1c 6.5 or Less
event count · % of participants
2.3% (n=129) vs 0% (n=129) placebo @ 26wk*25 mg QDa,c,e,f
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
show 1 more dose
2.3% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
7.4% (n=618) vs 1.9% (n=617) placebo @ 52wk*5 mgc,e,f
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 46 Participants as posted
HbA1c 7.0 or Less
event count · % of participants
7.8% (n=129) vs 0.8% (n=129) placebo @ 26wk*25 mg QDa,c,e,f
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 10 participants as posted
show 1 more dose
8.4% (n=131) vs 0.8% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
17.6% (n=618) vs 7.1% (n=617) placebo @ 52wk*5 mgc,e,f
NCT00954447 · Phase 3 · registry result, not featured evidence · converted to % from 109 Participants as posted
HbA1c Decrease 0 5
responder rate · % of participants
60.9% (n=404) vs 37.6% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,e,g
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
55.4% (n=101) vs 36% (n=100) placebo @ 24wkc,e,g
NCT02897349 · Phase 3 · registry result, not featured evidence
HbA1c Decrease 0.5
event count · % of participants
54.3% (n=129) vs 31% (n=129) placebo @ 26wk*25 mg QDa,h,c,i
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
show 1 more dose
53.4% (n=131) vs 31% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 70 participants as posted
21.1% (n=171) vs 15.9% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,h,c,i
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 36 participant as posted
show 1 more dose
21.8% (n=225) vs 15.9% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 49 participant as posted
HbA1c Less Than 6 5
responder rate · % of participants
36.7% (n=90) vs 12.2% (n=90) placebo @ 16wka,c,j
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
show 2 more doses
21.4% (n=98) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
30% (n=60) vs 12.2% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
15.4% (n=52) vs 9.4% (n=53) placebo @ 26wk5 mga,c,j
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more dose
16.7% (n=6) vs 9.4% (n=53) placebo @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
HbA1c Less Than 7%
event count · % of participants
44.4% (n=207) vs 18.3% (n=104) placebo @ 26wk*25 mg QDa,h,c,e,i
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 92 participants as posted
show 1 more dose
51.6% (n=213) vs 18.3% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 110 participants as posted
39.2% (n=171) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 1000 mg bida,h,c,e,i
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 67 participant as posted
show 1 more dose
25.3% (n=225) vs 30% (n=170) metformin @ 54wk*linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination · converted to % from 57 participant as posted
PPG 2h Change mg/dL
absolute change · mmol/L
3.08 vs 3.14 Voglibose mmol/L @ 24wk*25 mg QDa,k,c,e
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted
show 7 more doses
3.35 vs 2.92 Voglibose mmol/L*25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 60.4 mg/dL as posted
3.08 vs 3.14 Voglibose mmol/L @ 24wk*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.5 mg/dL as posted
3.54 vs 2.92 Voglibose mmol/L*12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 63.8 mg/dL as posted
3.1 vs 3.14 Voglibose mmol/L @ 24wk*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 55.9 mg/dL as posted
2.92 vs 2.92 Voglibose mmol/L*50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 52.6 mg/dL as posted
3.57 vs 3.14 Voglibose mmol/L @ 24wk*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 64.3 mg/dL as posted
3.61 vs 2.92 Voglibose mmol/L*6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence · converted to mmol/L from 65 mg/dL as posted
-2.71 vs 1.01 placebo mmol/L @ 24wk*k,c,e
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -48.86 mg/dL as posted
3 other source trials
-1.78 vs 0 placebo mmol/L @ 24wk*
NCT02897349 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -32.01 mg/dL as posted
-2.15 vs -2.04 placebo mmol/L @ 24wk*5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -38.74 mg/dL as posted
-1.86 vs 1.38 placebo mmol/L @ 24wk*
NCT00621140 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -33.51 mg/dL as posted
Triglyceride Change mg/dL
absolute change · mg/dL
-16.4 vs -7.8 Pioglitazone 45 mg + Metformin mg/dL @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metforminc,e,l
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.7 vs 5.2 Glimepiride mg/dL @ 432wkc,e,l
NCT01243424 · Phase 3
Dropout rate
40.3%25 mg QDm
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
36.6%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
18.3%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
21.1%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
20%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
11%
NCT00968708 · Phase 3
14.9%
NCT01456130 · Phase 3 · registry result, not featured evidence
44.3%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
46.4%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.8%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
6.1%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
36.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
38.8%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
20.5%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
37.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
17.5%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
17.1%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
0%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
4.5%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
30%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
21.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
24.2%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
15.4%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.1%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.3%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
11.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
10.8%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
13.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
23.2%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
17.1%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
23.2%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
19.6%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
22.3%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
21.4%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
17.4%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
25.3%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
24.6%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1.9%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
5.7%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
2.6%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
6.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
3.8%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
4.8%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
3.8%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
6.3%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
28.9%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
27.3%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
31.1%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
38.6%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
7.3%n
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
7.5%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
4.3%
NCT01243424 · Phase 3
0%
NCT02467478 · Phase 4 · registry result, not featured evidence
15%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
24%
NCT01897532 · Phase 4 · registry result, not featured evidence
5.3%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
20%
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
14%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
11.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
4.1%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
5.8%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
3.8%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
9.9%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
11.6%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
9.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
10.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.8%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
22.2%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
28.6%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
33.8%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
27.8%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
6.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
9%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
6.8%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
11.3%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
2.4%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
3.7%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
12.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
6.8%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.7%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
24.5%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.9%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
17%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
20.4%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
9.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
21.2%
NCT00740051 · Phase 3 · registry result, not featured evidence
5.8%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
5.4%
NCT00621140 · Phase 3 · registry result, not featured evidence
4.5%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
7.2%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
4.7%25 mg QDm
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
0.8%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.5%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.3%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
5.6%
NCT00968708 · Phase 3
6%
NCT01456130 · Phase 3 · registry result, not featured evidence
8.4%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
6.8%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
1.1%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
2%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
0%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
6.2%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
7.4%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
3.6%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
6.2%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
9.6%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
4.5%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
—25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
—25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
3.2%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
1.6%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
1.5%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.1%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.8%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.8%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
3.7%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3.7%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
3%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
4.1%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
3.3%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
3%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
—25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
—12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
3.8%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
—Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
3.8%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
—25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
—6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
1.2%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
4.4%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
6.8%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
—12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
2.9%n
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
1.7%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
—
NCT01243424 · Phase 3
—
NCT02467478 · Phase 4 · registry result, not featured evidence
—5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
10.3%
NCT01897532 · Phase 4 · registry result, not featured evidence
4%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
—Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
—Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
—
NCT02350478 · Phase 4 · registry result, not featured evidence
0%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.3%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.9%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
2.9%
NCT02897349 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
2.2%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
—25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
—5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
4.2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
2%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.9%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
4.8%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
3.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.9%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
4.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
3.4%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
2%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
1.5%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.7%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
1.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.4%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.1%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
1.8%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
4%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
6.4%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.8%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
4.9%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
2.6%
NCT00740051 · Phase 3 · registry result, not featured evidence
1.5%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
1.5%
NCT00621140 · Phase 3 · registry result, not featured evidence
1.3%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
3.6%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Serious AEs
5.4%25 mg QDm
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
6.1%12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
3.8%12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
2.7%25 mg
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
33.6%
NCT00968708 · Phase 3
9%
NCT01456130 · Phase 3 · registry result, not featured evidence
11%25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
9.9%12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
2.2%Alogliptin Monotherapy
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
0%Metformin + Alogliptin Add-on Ther
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
1.6%Pioglitazone + Alogliptin Add-on T
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
16.3%25 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
16.7%12.5 mg
NCT00306384 · Phase 3 · registry result, not featured evidence
0.9%25 mg QD
NCT01023581 · Phase 3 · registry result, not featured evidence
3.6%12.5 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence
1.8%alogliptin 12.5 mg BID + metformin 1000 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
1.9%alogliptin 12.5 mg BID + metformin 500 mg BID
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
8%25 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence
13.6%25 mg QD + 30 mg QD
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
5%Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
4.7%25 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
3.9%12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
0.8%25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
4.6%25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
3.8%25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
2.3%12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
1.5%12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
0.6%25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
4.9%25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
0.6%12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
6.5%25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
2.5%12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence
3.9%25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
2.8%12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence
5.6%25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
5.4%12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence
2%25 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
3.4%25 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
10.7%12.5 mg QD and 1-6 mg QD or BID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
4.9%12.5 mg QD and 500 mg BID or 750 mg TID
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
1%25 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
2.9%12.5 mg QD
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
6.7%Alogliptin 25 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
5.6%Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
1.8%alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0.9%alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
0%12.5 mg QD
NCT01263483 · Phase 2/3 · registry result, not featured evidence
1.3%25 mg QD + 0.2 mg TID
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
8.2%25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
7.9%12.5 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
5.2%50 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
2.1%6.25 mg QD
NCT01263496 · Phase 2 · registry result, not featured evidence
1.3%25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.4%12.5 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%50 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.5%6.25 mg QD
NCT01263470 · Phase 2 · registry result, not featured evidence
2.2%25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%12.5 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
2.4%6.25 mg QD
NCT00755846 · Phase 2 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
0%12.5 mg
NCT00957268 · Phase 1 · registry result, not featured evidence
10%Roflumilast + Alogliptin
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
0%Roflumilast Alone
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
3.2%n
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 57 more results
3.4%
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4%5 mg
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
46.4%
NCT01243424 · Phase 3
7.1%
NCT02467478 · Phase 4 · registry result, not featured evidence
0%5 mg per day
NCT02372630 · Phase 4 · registry result, not featured evidence
37%
NCT01897532 · Phase 4 · registry result, not featured evidence
—5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.6%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
25%5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
0.8%Linagliptin In-hospital
NCT02004366 · Phase 4 · registry result, not featured evidence
13%Linagliptin on Discharge
NCT02004366 · Phase 4 · registry result, not featured evidence
15.1%Linagliptin+50%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
23.1%Linagliptin+80%Glargine Dose on d/
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
15%
NCT02350478 · Phase 4 · registry result, not featured evidence
5.3%
NCT01969084 · Phase 4 · registry result, not featured evidence
1.3%5 mg
NCT01512979 · Phase 4 · registry result, not featured evidence
1.9%5 mg + Metformin
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
0.6%5 mg once daily + metformin once daily
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
9.6%
NCT02897349 · Phase 3 · registry result, not featured evidence
5.2%25 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
0.9%10 mg + 5 mg
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
9.3%5 mg
NCT01792518 · Phase 3 · registry result, not featured evidence
3.6%25 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
4.5%10 mg + 5 mg
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
0%5 mg
NCT01708902 · Phase 3 · registry result, not featured evidence
—5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
1.4%5 mg QD
NCT01708902 · Phase 3 · registry result, not featured evidence
3.2%5 mg QD, then 2.5 mg / Metformin after week 12
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.5%2.5 mg / 1000 mg
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
—2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
1.4%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.7%2.5 mg / 1000 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
0.7%2.5 mg / 500 mg BID
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
6.7%5 mg
NCT01183013 · Phase 3 · registry result, not featured evidence
7.1%5 mg + 15 mg / 5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
11.3%5 mg + 30 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
7.5%5 mg + 45 mg
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
24.8%5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
0.5%5 mg
NCT01214239 · Phase 3 · registry result, not featured evidence
2%5 mg once daily
NCT01215097 · Phase 3 · registry result, not featured evidence
2.2%5 mg tablet
NCT00996658 · Phase 3 · registry result, not featured evidence
8.2%A-GI+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
9.8%Bigu+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
7.6%Glin+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
2.7%Glit+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
4.9%SU+Lina
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
0.9%5 mg
NCT01194830 · Phase 3 · registry result, not featured evidence
13.8%5 mg
NCT00954447 · Phase 3 · registry result, not featured evidence
8.2%linagliptin 2.5 mg bid + metformin 1000 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5.3%linagliptin 2.5 mg bid + metformin 500 mg bid
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
8.6%5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
0.7%
NCT00740051 · Phase 3 · registry result, not featured evidence
3.1%
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
3%
NCT00621140 · Phase 3 · registry result, not featured evidence
2.2%5 mg once daily
NCT01012037 · Phase 2 · registry result, not featured evidence
4%2.5 mg twice daily
NCT01012037 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
25 mg QDm
urinary tract infection 7% (placebo 7.8%)
diarrhoea 6.2% (placebo 5.4%)
nasopharyngitis 6.2% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 69 more results
12.5 mg QD
arthralgia 6.9% (placebo 2.3%)
urinary tract infection 6.1% (placebo 7.8%)
headache 5.3% (placebo 4.7%)
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3
25 mg QD
nasopharyngitis 7.6% (placebo 7.8%)
headache 6.8% (placebo 4.7%)
upper respiratory tract infection 4.5% (placebo 9.4%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
12.5 mg QD
nasopharyngitis 9% (placebo 7.8%)
headache 7.5% (placebo 4.7%)
back pain 5.3% (placebo 4.7%)
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
25 mg
headache 18.7% (placebo 10.5%)
hyperglycaemia 12% (placebo 11.8%)
diarrhoea 9.3% (placebo 9.2%)
NCT02856113 · Phase 3 · Type 2 Diabetes · phase 3
renal impairment 7.5% (placebo 6.5%)
hypertension 7.1% (placebo 7.4%)
hypoglycaemia 6.2% (placebo 5.9%)
NCT00968708 · Phase 3
nasopharyngitis 35.8%
upper respiratory tract inflammation 11.9%
arthralgia 7.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
25 mg
upper respiratory tract infection 10.3%
hypertension 7.6%
nasopharyngitis 7.6%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
12.5 mg
upper respiratory tract infection 9.6%
nasopharyngitis 8.9%
diarrhoea 6.9%
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 6.5% (placebo 1.1%)
upper respiratory tract infection 5.4% (placebo 3.3%)
blood triglycerides increased 2.2% (placebo 1.1%)
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
upper respiratory tract infection 3% (placebo 3.3%)
blood triglycerides increased 2% (placebo 1.1%)
urinary tract infection 2% (placebo 6.5%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
hyperlipidaemia 21.3% (placebo 1.1%)
urinary tract infection 6.6% (placebo 6.5%)
upper respiratory tract infection 3.3% (placebo 3.3%)
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
25 mg
hypertension 14.5%
urinary tract infection 11.7%
nasopharyngitis 11.6%
NCT00306384 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertension 14.8%
upper respiratory tract infection 11.6%
urinary tract infection 11.1%
NCT00306384 · Phase 3 · registry result, not featured evidence
25 mg QD
hyperglycaemia 17% (placebo 26.4%)
nasopharyngitis 6.3% (placebo 1.9%)
headache 5.4% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
12.5 mg BID
hyperglycaemia 11.8% (placebo 26.4%)
headache 4.5% (placebo 2.8%)
creatinine renal clearance decreased 3.6% (placebo 3.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence
alogliptin 12.5 mg BID + metformin 1000 mg BID
creatinine renal clearance decreased 7.9% (placebo 3.8%)
diarrhoea 7% (placebo 2.8%)
dyspepsia 7% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
alogliptin 12.5 mg BID + metformin 500 mg BID
hyperglycaemia 7.5% (placebo 26.4%)
upper respiratory tract infection 7.5% (placebo 2.8%)
headache 6.6% (placebo 2.8%)
NCT01023581 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 20% (placebo 4.2%)
anaemia 12% (placebo 4.2%)
constipation 8% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence
25 mg QD + 30 mg QD
hypoglycaemia 13.6% (placebo 0%)
nasopharyngitis 13.6% (placebo 4.2%)
constipation 9.1% (placebo 4.2%)
NCT00655863 · Phase 3 · registry result, not featured evidence · combination
Alogliptin 25 mg; Pioglitazone 30 mg; Metformin
upper respiratory tract infection 7.2%
nasopharyngitis 6.9%
hypertension 5.9%
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 7% (placebo 4.7%)
upper respiratory tract infection 6.2% (placebo 3.9%)
abdominal pain upper 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence
12.5 mg
hypertriglyceridaemia 5.5% (placebo 2.3%)
hypertension 4.7% (placebo 3.1%)
urinary tract infection 4.7% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence
25 mg + 15 mg
influenza 6.2% (placebo 2.3%)
nasopharyngitis 6.2% (placebo 3.9%)
oedema peripheral 5.4% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 30 mg
nasopharyngitis 6.9% (placebo 3.9%)
back pain 6.2% (placebo 3.9%)
influenza 6.2% (placebo 2.3%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg + 45 mg
diarrhoea 5.4% (placebo 8.5%)
headache 4.6% (placebo 4.7%)
oedema peripheral 4.6% (placebo 1.6%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 15 mg
hypertension 6.9% (placebo 3.1%)
nasopharyngitis 6.2% (placebo 3.9%)
dizziness 5.4% (placebo 3.1%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
dizziness 3.8% (placebo 3.1%)
nasopharyngitis 3.8% (placebo 3.9%)
upper respiratory tract infection 3.8% (placebo 3.9%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 45 mg
back pain 9.2% (placebo 3.9%)
dizziness 4.6% (placebo 3.1%)
headache 4.6% (placebo 4.7%)
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
25 mg
headache 6.7%
urinary tract infection 3%
oedema peripheral 1.2%
NCT00395512 · Phase 3 · registry result, not featured evidence
25 mg + 30 mg
headache 12.2%
back pain 6.1%
urinary tract infection 5.5%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
12.5 mg + 30 mg
headache 8.6%
urinary tract infection 3.7%
back pain 1.8%
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 7% (placebo 6.2%)
influenza 5.5% (placebo 4.1%)
oedema peripheral 5.5% (placebo 7.2%)
NCT00286494 · Phase 3 · registry result, not featured evidence
12.5 mg QD
oedema peripheral 6.1% (placebo 7.2%)
upper respiratory tract infection 5.6% (placebo 5.2%)
nausea 4.5% (placebo 2.1%)
NCT00286494 · Phase 3 · registry result, not featured evidence
25 mg QD
diarrhoea 3.4% (placebo 5.8%)
nasopharyngitis 3.4% (placebo 5.8%)
bronchitis 2.9% (placebo 1.9%)
NCT00286442 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 6.6% (placebo 3.8%)
nasopharyngitis 5.6% (placebo 5.8%)
upper respiratory tract infection 4.7% (placebo 6.7%)
NCT00286442 · Phase 3 · registry result, not featured evidence
25 mg QD
headache 5.6% (placebo 3%)
hypertension 5.6% (placebo 2%)
urinary tract infection 5.1% (placebo 3%)
NCT00286468 · Phase 3 · registry result, not featured evidence
12.5 mg QD
urinary tract infection 4.4% (placebo 3%)
diarrhoea 3.9% (placebo 0%)
hypertriglyceridaemia 3.9% (placebo 2%)
NCT00286468 · Phase 3 · registry result, not featured evidence
25 mg QD and 1-6 mg QD or BID
nasopharyngitis 37.5%
upper respiratory tract inflammation 10.5%
fall 7.9%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 36.6%
diabetic retinopathy 6.9%
constipation 5.5%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 1-6 mg QD or BID
nasopharyngitis 30.7%
upper respiratory tract inflammation 6.7%
back pain 5.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD and 500 mg BID or 750 mg TID
nasopharyngitis 31%
back pain 6.3%
headache 6.3%
NCT01318135 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 19.2%
upper respiratory tract inflammation 11.5%
back pain 3.8%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 19%
gastroenteritis 3.8%
upper respiratory tract inflammation 1.9%
NCT01318083 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 25 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 28.6%
back pain 5.7%
arthralgia 4.8%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
Alogliptin 12.5 mg QD and Voglibose 0.2 mg TID
nasopharyngitis 35.2%
upper respiratory tract inflammation 11.1%
back pain 7.4%
NCT01263509 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 25 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 11.5%
blood creatine phosphokinase increased 3.5%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
alogliptin 12.5 mg QD; pioglitazone 15 or 30 mg QD
nasopharyngitis 4.5%
blood creatine phosphokinase increased 0%
dental caries 0%
NCT01318070 · Phase 2/3 · registry result, not featured evidence · combination
12.5 mg QD
nasopharyngitis 22.4%
eczema 1.3%
NCT01263483 · Phase 2/3 · registry result, not featured evidence
25 mg QD + 0.2 mg TID
nasopharyngitis 16.5%
eczema 0%
NCT01263483 · Phase 2/3 · registry result, not featured evidence · combination
25 mg QD
nasopharyngitis 33%
headache 7.2%
upper respiratory tract inflammation 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 28.7%
bronchitis 5.9%
back pain 5%
NCT01263496 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 35.1%
blood creatine phosphokinase increased 8.2%
back pain 7.2%
NCT01263496 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 30.2%
upper respiratory tract inflammation 8.3%
back pain 7.3%
NCT01263496 · Phase 2 · registry result, not featured evidence
25 mg QD
nasopharyngitis 12.5% (placebo 6.7%)
headache 6.3% (placebo 5.3%)
abdominal distension 3.8% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
12.5 mg QD
nasopharyngitis 8.3% (placebo 6.7%)
flatulence 4.8% (placebo 2.7%)
urticaria 3.6% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 10.1% (placebo 6.7%)
blood creatine phosphokinase increased 5.1% (placebo 2.7%)
abdominal distension 2.5% (placebo 0%)
NCT01263470 · Phase 2 · registry result, not featured evidence
6.25 mg QD
nasopharyngitis 6.3% (placebo 6.7%)
bronchitis 3.8% (placebo 1.3%)
flatulence 2.5% (placebo 2.7%)
NCT01263470 · Phase 2 · registry result, not featured evidence
25 mg QD
headache 8.9% (placebo 7.3%)
abdominal pain upper 6.7% (placebo 0%)
dizziness 6.7% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
12.5 mg QD
rash 9.1% (placebo 2.4%)
abdominal pain 4.5% (placebo 0%)
arthralgia 4.5% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
100 mg QD
nausea 11.4% (placebo 0%)
headache 9.1% (placebo 7.3%)
urinary tract infection 9.1% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
50 mg QD
diarrhoea 7% (placebo 7.3%)
headache 7% (placebo 7.3%)
urinary tract infection 7% (placebo 9.8%)
NCT00755846 · Phase 2 · registry result, not featured evidence
6.25 mg QD
urinary tract infection 7.1% (placebo 9.8%)
abdominal pain upper 4.8% (placebo 0%)
dizziness 4.8% (placebo 0%)
NCT00755846 · Phase 2 · registry result, not featured evidence
25 mg
rash papular 25%
abdominal pain 0%
blood creatine phosphokinase increased 0%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
blood creatine phosphokinase increased 14.3%
haematocrit decreased 14.3%
haemoglobin decreased 14.3%
NCT00957268 · Phase 1 · registry result, not featured evidence
25 mg
headache 18.2%
fatigue 9.1%
nausea 9.1%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
diarrhoea 20%
neutrophil count decreased 20%
pyrexia 20%
NCT00957268 · Phase 1 · registry result, not featured evidence
12.5 mg
abdominal pain 25%
gastritis 12.5%
headache 12.5%
NCT00957268 · Phase 1 · registry result, not featured evidence
headache 30%
nausea 20%
constipation 10%
NCT01664624 · Phase 1 · registry result, not featured evidence · combination
nausea 50%
diarrhoea 40%
vomiting 30%
NCT01664624 · Phase 1 · registry result, not featured evidence · monotherapy
n
hypoglycaemia 22.7% (placebo 14.8%)
upper respiratory tract infection 5.8% (placebo 9.1%)
hyperglycaemia 5.6% (placebo 8.7%)
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 50 more results
hyperglycaemia 5.2% (placebo 14.7%)
nasopharyngitis 5.2% (placebo 5.1%)
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
5 mg
hypoglycaemia 20.8% (placebo 12.1%)
headache 15.6% (placebo 15.5%)
blood ketone body increased 10.4% (placebo 3.4%)
NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3
nasopharyngitis 17.5%
hypertension 14.2%
hyperglycaemia 14%
NCT01243424 · Phase 3
hypoglycaemia 29.3% (placebo 28.8%)
hypertension 6.2% (placebo 6.7%)
hyperglycaemia 6% (placebo 6.9%)
NCT01897532 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 33.8% (placebo 25.2%)
viral upper respiratory tract infection 7.3% (placebo 5.3%)
urinary tract infection 6.6% (placebo 6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
5 mg
hypoglycaemia 38.5% (placebo 25.2%)
viral upper respiratory tract infection 21.2% (placebo 5.3%)
bronchitis 9.6% (placebo 2.6%)
NCT02240680 · Phase 4 · registry result, not featured evidence
infections 5.5%
renal 4.7%
surgical reintervention 4.7%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
musculoskeletal 1.1%
skin 1.1%
NCT02004366 · Phase 4 · registry result, not featured evidence
gastrointestinal 1.1%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal 0%
hematologic 0%
infections 0%
NCT02004366 · Phase 4 · registry result, not featured evidence · combination
dorsal pain 5% (placebo 0%)
nausea 5% (placebo 4.3%)
toothache 5% (placebo 0%)
NCT02350478 · Phase 4 · registry result, not featured evidence
increased creatinine and bun, reduced gfr 5.3% (placebo 13.6%)
pneumonia 5.3% (placebo 0%)
cramping in the calf muscle during the graded exercise test 0% (placebo 4.5%)
NCT01969084 · Phase 4 · registry result, not featured evidence
5 mg
dyslipidaemia 14%
hyperglycaemia 12.7%
urinary tract infection 8.9%
NCT01512979 · Phase 4 · registry result, not featured evidence
5 mg + Metformin
dyslipidaemia 8.8%
headache 6.3%
urinary tract infection 6.3%
NCT01512979 · Phase 4 · registry result, not featured evidence · combination
5 mg once daily + metformin once daily
diarrhoea 18%
abdominal pain 6.7%
nausea 6.7%
NCT01438814 · Phase 4 · registry result, not featured evidence · combination
hypoglycaemia 17.3% (placebo 12.7%)
upper respiratory tract infection 13.5% (placebo 12.7%)
hyperuricaemia 5.8% (placebo 1%)
NCT02897349 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
viral upper respiratory tract infection 26.7% (placebo 22.2%)
blood ketone body increased 13.8% (placebo 10.2%)
back pain 6% (placebo 2.8%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
viral upper respiratory tract infection 15% (placebo 22.2%)
back pain 2.8% (placebo 2.8%)
contusion 2.8% (placebo 0.9%)
NCT02489968 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 13.2% (placebo 5.6%)
nasopharyngitis 7.1% (placebo 5.6%)
upper respiratory tract infection 2.2% (placebo 5.1%)
NCT01792518 · Phase 3 · registry result, not featured evidence
25 mg + 5 mg
nasopharyngitis 3.6% (placebo 7.3%)
lipase increased 2.7% (placebo 5.5%)
urinary tract infection 2.7% (placebo 6.4%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
10 mg + 5 mg
urinary tract infection 7.1% (placebo 6.4%)
nasopharyngitis 4.5% (placebo 7.3%)
lipase increased 3.6% (placebo 5.5%)
NCT01734785 · Phase 3 · registry result, not featured evidence · combination
5 mg
diarrhoea 3%
hyperuricaemia 3%
dizziness 0%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperglycaemia 16.9%
hyperuricaemia 5.6%
nasopharyngitis 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD
hyperuricaemia 7.5%
hyperglycaemia 4.8%
upper respiratory tract infection 4.1%
NCT01708902 · Phase 3 · registry result, not featured evidence
5 mg QD, then 2.5 mg / Metformin after week 12
hyperuricaemia 19.4%
dizziness 6.5%
hyperglycaemia 6.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg
hyperuricaemia 6.2%
hyperglycaemia 3.1%
diarrhoea 1.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 5.6%
hyperuricaemia 5.6%
upper respiratory tract infection 5.6%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 1000 mg BID
diarrhoea 9.5%
hyperuricaemia 7.5%
upper respiratory tract infection 7.5%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
2.5 mg / 500 mg BID
upper respiratory tract infection 8.2%
hyperuricaemia 5.4%
diarrhoea 4.8%
NCT01708902 · Phase 3 · registry result, not featured evidence · combination
5 mg
hyperglycaemia 10.4%
nasopharyngitis 7.4%
hypertension 6.7%
NCT01183013 · Phase 3 · registry result, not featured evidence
5 mg + 15 mg / 5 mg + 30 mg
diarrhoea 7.9%
nasopharyngitis 7.1%
back pain 6.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 30 mg
oedema 9%
dizziness 6.8%
oedema peripheral 6.8%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg + 45 mg
oedema peripheral 11.3%
back pain 9%
urinary tract infection 5.3%
NCT01183013 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 59.3%
nasopharyngitis 18.6%
hyperglycaemia 17.7%
NCT01087502 · Phase 3 · registry result, not featured evidence
5 mg
hyperlipidaemia 5.5% (placebo 3%)
hyperglycaemia 2% (placebo 4%)
NCT01214239 · Phase 3 · registry result, not featured evidence
5 mg once daily
hyperglycaemia 4.9% (placebo 5%)
hyperlipidaemia 4.4% (placebo 4%)
diarrhoea 2.4% (placebo 1%)
NCT01215097 · Phase 3 · registry result, not featured evidence
5 mg tablet
anaemia 7.1% (placebo 6.7%)
hyperglycaemia 6% (placebo 7.9%)
hypoglycaemia 5.5% (placebo 4.5%)
NCT00996658 · Phase 3 · registry result, not featured evidence
nasopharyngitis 41.2%
back pain 5.9%
constipation 5.9%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 36.6%
bronchitis 11%
arthralgia 6.1%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 45.5%
pharyngitis 7.6%
constipation 4.5%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 33.8%
upper respiratory tract inflammation 8.1%
arthralgia 5.4%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
nasopharyngitis 31.5%
hypoglycaemia 14%
contusion 7%
NCT01204294 · Phase 3 · registry result, not featured evidence · combination
5 mg
urinary tract infection 6.6% (placebo 3.3%)
hyperglycaemia 2.8% (placebo 9.2%)
NCT01194830 · Phase 3 · registry result, not featured evidence
5 mg
hypoglycaemia 30.3% (placebo 31.3%)
hyperglycaemia 14.3% (placebo 17.8%)
nasopharyngitis 11.3% (placebo 9.8%)
NCT00954447 · Phase 3 · registry result, not featured evidence
linagliptin 2.5 mg bid + metformin 1000 mg bid
diabetes mellitus 9.9%
diarrhoea 7%
nasopharyngitis 7%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
linagliptin 2.5 mg bid + metformin 500 mg bid
hyperglycaemia 12.9%
diabetes mellitus 8%
glomerular filtration rate decreased 6.2%
NCT00915772 · Phase 3 · registry result, not featured evidence · combination
5 mg
hypoglycaemia 22.8% (placebo 16.5%)
nasopharyngitis 10.5% (placebo 8.9%)
diarrhoea 5.6% (placebo 2.5%)
NCT01084005 · Phase 3 · registry result, not featured evidence
hyperglycaemia 14.6%
nasopharyngitis 9.9%
dizziness 7.3%
NCT00740051 · Phase 3 · registry result, not featured evidence
nasopharyngitis 9.3% (placebo 8.5%)
upper respiratory tract infection 3.5% (placebo 7.7%)
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
hyperglycaemia 8.6% (placebo 22.8%)
NCT00621140 · Phase 3 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 4 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dThe assessment timepoint is not available for both results.
  5. eTreatment context has not been resolved for both arms.
  6. fAssessment timepoints differ: 52 weeks versus 26 weeks.
  7. gAssessment timepoints differ: 24 weeks versus 52 weeks.
  8. hThe reported result categories differ.
  9. iAssessment timepoints differ: 54 weeks versus 26 weeks.
  10. jAssessment timepoints differ: 26 weeks versus 16 weeks.
  11. kTrial phases differ: Phase 3 versus Phase 2.
  12. lAssessment timepoints differ: 432 weeks versus 52 weeks.
  13. mPopulation comparability has not been reviewed for 65 of these studies.
  14. nPopulation comparability has not been reviewed for 55 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Alogliptin

Rescue 19.5% (n=128) vs 40.3% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 25 participants as posted
show 5 more results
9% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 18 participants as posted
15.7% (n=198) vs 28.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 31 participants as posted
20.6% (n=131) vs 40.3% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 27 participants as posted
9.7% (n=196) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 19 participants as posted
14.9% (n=201) vs 28.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 30 participants as posted
HbA1c 7 5 or Less 25.6% (n=129) vs 3.9% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 33 participants as posted
show 7 more results
67.2% (n=131) vs 39.1% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 88 participants as posted
70.9% (n=199) vs 48.5% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 141 participants as posted
56.6% (n=198) vs 33.3% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 112 participants as posted
16.8% (n=131) vs 3.9% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
60.9% (n=133) vs 39.1% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 81 participants as posted
64.5% (n=197) vs 48.5% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 127 participants as posted
46.3% (n=203) vs 33.3% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 94 participants as posted
HbA1c Decrease 1 0 36.4% (n=129) vs 13.2% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 47 participants as posted
show 9 more results
29.8% (n=131) vs 10.9% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 39 participants as posted
36.7% (n=199) vs 12.4% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 73 participants as posted
30% (n=207) vs 8.7% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 62 participants as posted
29.8% (n=198) vs 13.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 59 participants as posted
31.3% (n=131) vs 13.2% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 41 participants as posted
28.6% (n=133) vs 10.9% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 38 participants as posted
32.5% (n=197) vs 12.4% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 64 participants as posted
28.6% (n=213) vs 8.7% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 61 participants as posted
18.7% (n=203) vs 13.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 38 participants as posted
HbA1c Decrease 1 5 17.8% (n=129) vs 4.7% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 23 participants as posted
show 9 more results
12.2% (n=131) vs 4.7% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 16 participants as posted
18.6% (n=199) vs 5.2% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 37 participants as posted
11.6% (n=207) vs 5.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
12.1% (n=198) vs 7.1% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 24 participants as posted
16.8% (n=131) vs 4.7% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 22 participants as posted
8.3% (n=133) vs 4.7% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
16.2% (n=197) vs 5.2% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 32 participants as posted
9.4% (n=213) vs 5.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 20 participants as posted
6.4% (n=203) vs 7.1% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 13 participants as posted
HbA1c Decrease 2 0 8.5% (n=129) vs 0% (n=129) placebo @ 26wk25 mg QD
event count · % of participants
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
show 9 more results
4.6% (n=131) vs 1.6% (n=64) placebo @ 26wk*25 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 6 participants as posted
7% (n=199) vs 3.1% (n=97) placebo @ 26wk*25 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 14 participants as posted
2.4% (n=207) vs 3.8% (n=104) placebo @ 26wk*25 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
6.1% (n=198) vs 4% (n=99) placebo @ 26wk*25 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
8.4% (n=131) vs 0% (n=129) placebo @ 26wk*12.5 mg QD
NCT00286429 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to % from 11 participants as posted
2.3% (n=133) vs 1.6% (n=64) placebo @ 26wk*12.5 mg QD
NCT00286455 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to % from 3 participants as posted
6.1% (n=197) vs 3.1% (n=97) placebo @ 26wk*12.5 mg QD
NCT00286494 · Phase 3 · registry result, not featured evidence · converted to % from 12 participants as posted
3.3% (n=213) vs 3.8% (n=104) placebo @ 26wk*12.5 mg QD
NCT00286442 · Phase 3 · registry result, not featured evidence · converted to % from 7 participants as posted
2.5% (n=203) vs 4% (n=99) placebo @ 26wk*12.5 mg QD
NCT00286468 · Phase 3 · registry result, not featured evidence · converted to % from 5 participants as posted
MACE Composite 12.7% (n=2701) vs 13.4% (n=2679) placebo
responder rate · % of participants
NCT00968708 · Phase 3
HbA1c Less Than 6 5 28.4% (n=67) @ 52wk
responder rate · % of participants
No placebo or comparator arm
HbA1c of < 6.5%
NCT01456130 · Phase 3 · registry result, not featured evidence
Fasting Glucose Change mg/dL -0.58 mmol/L @ 52wk
absolute change · mmol/L
No placebo or comparator arm
NCT01456130 · Phase 3 · registry result, not featured evidence · converted to mmol/L from -10.5 mg/dL as posted
HbA1c Less Than or Equal to 6.5 11.6% (n=164) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg
responder rate · % of participants
NCT00395512 · Phase 3 · registry result, not featured evidence
show 10 more results
26.2% (n=878) vs 24.8% (n=869) Glipizide @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.8% (n=878) vs 20.8% (n=869) Glipizide @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
26.4% (n=878) vs 21.8% (n=869) Glipizide @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.1% (n=878) vs 19% (n=869) Glipizide @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
27.4% (n=164) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
25.6% (n=873) vs 24.8% (n=869) Glipizide @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.5% (n=873) vs 20.8% (n=869) Glipizide @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
24.2% (n=873) vs 21.8% (n=869) Glipizide @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
23.5% (n=873) vs 19% (n=869) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
26.4% (n=163) vs 16.6% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
HbA1c 7 0 or Less 27.1% (n=129) vs 6.2% (n=129) placebo @ 26wk25 mg
responder rate · % of participants
NCT00328627 · Phase 3 · registry result, not featured evidence
show 18 more results
24.4% (n=164) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
22.7% (n=128) vs 6.2% (n=129) placebo @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
59.2% (n=878) vs 56.1% (n=869) Glipizide @ 26wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
55.5% (n=878) vs 47.4% (n=869) Glipizide @ 52wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
52.4% (n=878) vs 46.6% (n=869) Glipizide @ 78wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
48.5% (n=878) vs 42.8% (n=869) Glipizide @ 104wk25 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
54.6% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.1% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
60% (n=130) vs 6.2% (n=129) placebo @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
62.8% (n=164) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
56.4% (n=873) vs 56.1% (n=869) Glipizide @ 26wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
51.7% (n=873) vs 47.4% (n=869) Glipizide @ 52wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
48.8% (n=873) vs 46.6% (n=869) Glipizide @ 78wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
45.6% (n=873) vs 42.8% (n=869) Glipizide @ 104wk12.5 mg
NCT00856284 · Phase 3 · registry result, not featured evidence · combination
49.2% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.1% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
61.5% (n=130) vs 6.2% (n=129) placebo @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
53.4% (n=163) vs 33.7% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
HbA1c 7 5 or Less 55% (n=129) vs 24.8% (n=129) placebo @ 26wk25 mg
responder rate · % of participants
NCT00328627 · Phase 3 · registry result, not featured evidence
show 15 more results
44.5% (n=164) vs 55.8% (n=163) Pioglitazone 30 mg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
38.3% (n=128) vs 24.8% (n=129) placebo @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
64.9% (n=404) vs 47.1% (n=399) Pioglitazone 45 mg + Metformin @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
59.9% (n=404) vs 44.1% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
71.5% (n=130) vs 24.8% (n=129) placebo @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
72.3% (n=130) vs 24.8% (n=129) placebo @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
78.5% (n=130) vs 24.8% (n=129) placebo @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
72% (n=164) vs 55.8% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
77.7% (n=130) vs 24.8% (n=129) placebo @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
73.8% (n=130) vs 24.8% (n=129) placebo @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
80.8% (n=130) vs 24.8% (n=129) placebo @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
72.4% (n=163) vs 55.8% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
81.1% (n=90) vs 53.3% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
80.6% (n=98) vs 53.3% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
85% (n=60) vs 53.3% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
HbA1c Decrease 1 0 47.3% (n=129) vs 16.3% (n=129) placebo @ 26wk25 mg
responder rate · % of participants
NCT00328627 · Phase 3 · registry result, not featured evidence
show 15 more results
43.3% (n=164) vs 54.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg
NCT00395512 · Phase 3 · registry result, not featured evidence
33.6% (n=128) vs 16.3% (n=129) placebo @ 26wk12.5 mg
NCT00328627 · Phase 3 · registry result, not featured evidence
42.3% (n=404) vs 20.3% (n=399) Pioglitazone 45 mg + Metformin @ 26wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
35.6% (n=404) vs 17.3% (n=399) Pioglitazone 45 mg + Metformin @ 52wkAlogliptin 25 mg; Pioglitazone 30 mg; Metformin
NCT00432276 · Phase 3 · registry result, not featured evidence · combination
66.9% (n=130) vs 16.3% (n=129) placebo @ 26wk25 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
69.2% (n=130) vs 16.3% (n=129) placebo @ 26wk25 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
72.3% (n=130) vs 16.3% (n=129) placebo @ 26wk25 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
75.6% (n=164) vs 54.6% (n=163) Pioglitazone 30 mg @ 26wk25 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
69.2% (n=130) vs 16.3% (n=129) placebo @ 26wk12.5 mg + 15 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
73.1% (n=130) vs 16.3% (n=129) placebo @ 26wk12.5 mg + 30 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
73.1% (n=130) vs 16.3% (n=129) placebo @ 26wk12.5 mg + 45 mg
NCT00328627 · Phase 3 · registry result, not featured evidence · combination
68.1% (n=163) vs 54.6% (n=163) Pioglitazone 30 mg @ 26wk12.5 mg + 30 mg
NCT00395512 · Phase 3 · registry result, not featured evidence · combination
50% (n=90) vs 20% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · monotherapy
45.9% (n=98) vs 20% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination
46.7% (n=60) vs 20% (n=90) placebo @ 16wk
NCT01289119 · Phase 3 · registry result, not featured evidence · combination

+ 47 further endpoints in the CSV export.

Linagliptin

HbA1c Less Than 7 37.8% (n=149) vs 14.6% (n=147) placebo @ 24wk5 mg
absolute value · percentage points
NCT02240680 · Phase 4 · registry result, not featured evidence
show 12 more results
22.1% (n=108) vs 11.8% (n=110) Glimepiride @ 52wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
19.4% (n=108) vs 9.1% (n=110) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
38.9% (n=149) vs 8.3% (n=72) placebo @ 24wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
41.9% (n=160) vs 11.5% (n=78) placebo @ 24wk5 mg
NCT01084005 · Phase 3 · registry result, not featured evidence
29.2% (n=742) vs 8.1% (n=247) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
31.2% (n=778) vs 9.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
26.2% (n=485) vs 9.2% (n=163) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3% (n=513) vs 11.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
42.9% (n=252) vs 30.5% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
42.9% (n=252) vs 30.5% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
25.2% (n=306) vs 11.6% (n=147) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
28.2% (n=333) vs 15.3% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Less Than 6 5 9.9% (n=115) vs 6.7% (n=120) Glimepiride @ 52wk5 mg
absolute value · percentage points
NCT01087502 · Phase 3 · registry result, not featured evidence
show 9 more results
6.1% (n=115) vs 5% (n=120) Glimepiride @ 12wk5 mg
NCT01087502 · Phase 3 · registry result, not featured evidence
13.1% (n=777) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
13.1% (n=778) vs 4.2% (n=262) placebo @ 24wk
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.4% (n=511) vs 2.3% (n=171) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
10.7% (n=513) vs 3.4% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
17.5% (n=252) vs 14.1% (n=128) placebo @ 24wk
NCT00641043 · Phase 3 · registry result, not featured evidence · combination
10.6% (n=329) vs 4.9% (n=162) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
10.8% (n=333) vs 4.9% (n=163) placebo @ 24wk
NCT00621140 · Phase 3 · registry result, not featured evidence
HbA1c Reduction 0 5 58.2% (n=778) vs 30.2% (n=262) placebo @ 24wk
absolute value · percentage points
NCT00602472 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
show 1 more result
49.7% (n=513) vs 21.7% (n=175) placebo @ 24wk
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
PPG Increment Over FPG mg/dL -1.72 vs 0.61 placebo mmol/L @ 24wk
absolute value · mmol/L
NCT00601250 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3 · converted to mmol/L from -30.9 mg/dL as posted
Treatment Failure 50% (n=6) vs 60% (n=5) placebo @ 26wk5 mg
responder rate · % of participants
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Time to Treatment Failure 2.37 vs 2.16 placebo months5 mg
time to event · months
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3 · converted to months from 72.167 days as posted
Fasting Plasma Glucose Change mg/dL 10.29 vs 15.7 placebo mg @ 26wk5 mg
absolute change · mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 4 more results
0.12 vs 15.7 placebo mg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
-11.3 vs 0.2 placebo mg @ 24wk5 mg
NCT02240680 · Phase 4 · registry result, not featured evidence
12.4 vs 19.7 Glimepiride mg @ 432wk
NCT01243424 · Phase 3
-5.5 vs 0.7 placebo mg @ 24wk
NCT02897349 · Phase 3 · registry result, not featured evidence
Seated SBP 2.21 vs 1.3 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
5.16 vs 1.3 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
Seated DBP 2.26 vs 0.76 placebo mmHg @ 26wk5 mg
absolute change · mmHg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 1 more result
6.75 vs 0.76 placebo mmHg @ 26wk5 mg
NCT03429543 · Phase 3 · combination · Type 2 Diabetes · phase 3
MACE 4-point Composite 23.4% (n=3023) vs 23.7% (n=3010) Glimepiride @ 432wk
event count · % of participants
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Hypoglycemia and no Weight Gain 16% (n=3014) vs 10.2% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3
HbA1c Less Than 7 Without Weight Gain 17.4% (n=3014) vs 14.1% (n=3000) Glimepiride @ 432wk
absolute value · percentage points
Maintenance
NCT01243424 · Phase 3

+ 44 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Alogliptin's landscape · Linagliptin's landscape